Method for producing compounds for inhibiting SHP2 activity
An optimized method for synthesizing SHP2 inhibitor compounds addresses scalability issues by using specific reaction steps and forming pharmaceutically acceptable salts, enhancing yield and purity for large-scale production.
Patent Information
- Application Number
- CN201980064336.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-09-29
- Filing Date
- 2019-09-18
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2039-09-18
AI Technical Summary
Existing methods for synthesizing compounds that inhibit SHP2 activity are not suitable for large-scale manufacturing due to low yields, use of unstable starting materials, racemic intermediates, and lack of clarity on pharmaceutically acceptable salts, making them inefficient for producing compounds like (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine.
A method involving multiple reaction steps with specific protecting groups and leaving groups, including cyclization, reduction, oxidation, and salt formation, optimized for large-scale production of the compound, ensuring higher purity and yield, and allowing for the formation of pharmaceutically acceptable salts.
The optimized method enhances the scalability and efficiency of producing the SHP2 inhibitor compound, addressing the limitations of previous methods by improving yield and purity, and enabling the formation of well-defined pharmaceutically acceptable salts.
Smart Images

Figure CN112839715B_ABST
Abstract
Description
Background Art Technical Field
[0002] The present invention relates to (pharmaceutically acceptable) salts of compounds capable of inhibiting SHP2 activity and polymorphs thereof, as well as polymorphs of the free base form of the compounds, and / or methods for producing the compounds, their (pharmaceutically acceptable) salts and polymorphs thereof. Background Art
[0003] Src homology region-2 phosphatase (SHP2) is a non-receptor protein tyrosine phosphatase encoded by the PTPN11 gene that contributes to a variety of cellular functions, including proliferation, differentiation, cell cycle maintenance, and migration. SHP2 is involved in signaling through the Ras-mitogen-activated protein kinase, JAK-STAT, or phosphoinositide 3-kinase-AKT pathways.
[0004] A compound having formula I having the name (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine,
[0005]
[0006] As SHP2 inhibitors are described in WO / 2015 / 107495 A1, various methods of treatment and treatment are also described therein.
[0007] Src homology region-2 phosphatase (SHP2) is a non-receptor protein tyrosine phosphatase encoded by the PTPN11 gene that contributes to a variety of cellular functions, including proliferation, differentiation, cell cycle maintenance, and migration. SHP2 is involved in signaling through the Ras-mitogen-activated protein kinase, JAK-STAT, or phosphoinositide 3-kinase-AKT pathways.
[0008] SHP2 has two N-terminal Src homology 2 domains (N-SH2 and C-SH2), a catalytic domain (PTP) and a C-terminal tail. The two SH2 domains control the subcellular localization and functional regulation of SHP2. The molecule exists in an inactive, autoinhibitory conformation stabilized by a binding network involving residues from the N-SH2 and PTP domains. Exposure of the catalytic site by stimulation, such as cytokines or growth factors, leads to enzymatic activation of SHP2.
[0009] Mutations in the PTPN11 gene and subsequently in SHP2 have been identified in a variety of human diseases such as Noonan syndrome, Leopard syndrome, juvenile myelomonocytic leukemia, neuroblastoma, melanoma, acute myeloid leukemia, and breast, lung, and colon cancer. Therefore, SHP2 represents an attractive target for the development of new therapeutics for a variety of diseases. The compounds made according to the present invention meet the need for small molecules that inhibit SHP2 activity.
[0010] WO / 2015 / 107495A1 describes a method for producing a compound having formula I, which may be characterized by the following reaction scheme 1:
[0011] Scenario 1:
[0012]
[0013] The final compound produced by step g above is then reacted in Scheme 2 below:
[0014] Scenario 2:
[0015]
[0016] Thus a compound of formula I is obtained (the last compound in Scheme 2 above). The synthesis requires at least the 9 steps shown and is somewhat amenable to laboratory scale synthesis.
[0017] The manufacture is complicated and requires separation of diastereomers, for example in step g in the above reaction scheme 1. In addition, many intermediates do not crystallize and therefore they are used without taking advantage of the higher purity based on crystallization.
[0018] Additionally, a further chromatography step was used in the method.
[0019] Furthermore, the aldehyde starting material used for reaction a in Scheme 1 above is a compound known in the literature, but is not available in large quantities (only on a gram scale, e.g. from Aldlab Chemicals), exhibits some inherent instability making it advantageous to prepare and use the starting material immediately. It is therefore more problematic to use for large scale synthesis (e.g., manufacture on a kilogram or larger scale).
[0020] Furthermore, the cyclization (step d in Scheme 1 above) has only moderate yields, with the educt, the tosylate of the desired product and further impurities also being present and requiring separation.
[0021] The keto substrate product of step e in scheme 1) is partially racemic, even when enantiomerically pure aldehyde starting material is used, leading to the formation of four diastereomers in step f (which actually involves two steps, condensation and reduction), resulting in a 95:5 ratio of two major diastereomers that require further separation.
[0022] Furthermore, the synthesis involves many oily intermediates, as shown in the following scheme:
[0023] Option 1A:
[0024]
[0025] Thus, the method, while easily achievable, especially on a laboratory scale, is not ideal for large-scale manufacturing.
[0026] The compound added in reaction b in Scheme 2 is obtained in WO 2015 / 107495 A1 as the following "Intermediate 10":
[0027] Scenario 3:
[0028]
[0029] The problem here is the relatively low yield of the amine produced by reaction a in Scheme 3.
[0030] In addition, although WO 2015 / 107495 A1 generally mentions that pharmaceutically acceptable salts of compounds having Formula I can be obtained, specific reasons for obtaining such salts and specific examples of the salts are not described.
[0031] Furthermore, given the numerous potential salt-forming groups in Formula I, it is not at all clear whether any salts with well-defined stoichiometry can be formed. Summary of the invention
[0032] In a first aspect, the present invention provides a method for producing a compound of formula I as described above or a pharmaceutically acceptable salt, acid co-crystal, hydrate or other solvate thereof, the method comprising: reacting a compound of formula II with a compound of formula III according to the following reaction scheme:
[0033]
[0034] wherein A is the anion of the acid, LG is a leaving group, and n and m are, for example, 1, 2 or 3, such that the compound of Formula II is uncharged.
[0035] In a second aspect, the method of the present invention further comprises reacting a compound having formula IV with a compound having formula H nThe acid of A is reacted according to the following reaction scheme to give a compound having formula II:
[0036]
[0037] wherein R1 is a protecting group for a secondary amino group, HY is a chiral acid, A is an anion of the acid, and n and m are integers of 1, 2 or 3, such that the compound of Formula II is uncharged.
[0038] In a third aspect, the method of the present invention further comprises reacting a compound of formula V or a salt thereof with a chiral acid of formula HY according to the following reaction scheme to obtain a compound of formula IV:
[0039]
[0040] wherein R1 is a protecting group for a secondary amino group, and HY is a chiral acid.
[0041] In a fourth aspect, the method of the invention further comprises reacting a compound of formula VI according to the following reaction scheme to obtain a compound of formula V:
[0042]
[0043] Here, R1 is a protecting group for a secondary amino group, and R2 is an alkyl group, especially a tertiary alkyl group.
[0044] In a fifth aspect, the method of the present invention further comprises reducing a compound having formula VII to obtain a compound having formula VI according to the following reaction scheme:
[0045]
[0046] Wherein, R1 is a protecting group for a secondary amino group, and R2 is an alkyl group, preferably a tertiary alkyl group.
[0047] In a sixth aspect, the method of the invention further comprises reacting a compound having formula VIII with a compound having formula IX according to the following reaction scheme to obtain a compound having formula VII:
[0048]
[0049] Wherein, R1 is a protecting group for a secondary amino group, and R2 is an alkyl group, preferably a tertiary alkyl group.
[0050] In a seventh aspect, the method of the present invention further comprises oxidizing the compound of formula X according to the following reaction scheme to obtain a compound of formula VIII:
[0051]
[0052] Wherein, R1 is a protecting group for the secondary amino group.
[0053] In an eighth aspect, the method of the present invention further comprises cyclizing the compound of formula XI to obtain a compound of formula X according to the following reaction scheme:
[0054]
[0055] wherein R1 is a protecting group for a secondary amino group, Pr1O is a leaving group, and Pr2 is a substituted silyl protecting group.
[0056] In a ninth aspect, the method of the present invention further comprises protecting a compound having formula XII with a compound having formula Pr1H according to the following reaction scheme to obtain a compound having formula XI:
[0057]
[0058] wherein R1 is a protecting group for a secondary amino group, Pr1O is a leaving group, especially tosyl, and Pr2 is a substituted silyl protecting group, especially a trialkyl- or diphenylalkyl-silyl group, especially tert-butyldimethylsilyl.
[0059] In a tenth aspect, the method of the present invention further comprises reducing a compound having formula XIII to obtain a compound having formula XII according to the following reaction scheme:
[0060]
[0061] wherein R1 is a protecting group for a secondary amino group, Ra is an unsubstituted or substituted alkyl group or an unsubstituted or substituted aryl group, and Pr2 is a substituted silyl protecting group, especially a trialkyl- or diphenylalkyl-silyl group, especially tert-butyldimethylsilyl.
[0062] In an eleventh aspect, the method of the present invention further comprises reacting a compound having formula XIV with a compound having formula XV according to the following reaction scheme to obtain a compound having formula XIII:
[0063]
[0064] wherein R1 is a protecting group for a secondary amino group, Ra is an unsubstituted or substituted alkyl group or an unsubstituted or substituted aryl group, and Pr2 is a substituted silyl protecting group, especially a trialkyl- or diphenylalkyl-silyl group, especially tert-butyldimethylsilyl.
[0065] In a twelfth aspect, the method of the present invention further comprises reducing a compound having formula XVI to obtain a compound having formula XIV according to the following reaction scheme:
[0066]
[0067] wherein Pr2 is a substituted silyl protecting group, especially a trialkyl- or diphenylalkyl-silyl group, especially tert-butyldimethylsilyl, R3 is an alkyl group, and R4 is an alkyl group.
[0068] In a thirteenth aspect, the method of the present invention further comprises reacting an ester compound having formula XVII with a compound having formula R4ONHR3 according to the following reaction scheme to obtain a compound having formula XVI:
[0069]
[0070] wherein Pr2 is a substituted silyl protecting group, in particular a trialkyl- or diphenylalkyl-silyl group, in particular a tert-butyldimethylsilyl group, R3 is an alkyl group, R4 is an alkyl group, and R5 is an unsubstituted or substituted alkyl group or an unsubstituted or substituted aryl group.
[0071] In a fourteenth aspect, the method of the present invention further comprises protecting a compound having formula XVIII with a compound having formula Pr2HAL according to the following reaction scheme to obtain a compound having formula XVII:
[0072]
[0073] wherein Pr2 is a substituted silyl protecting group, especially a trialkyl- or diphenylalkyl-silyl group, especially tert-butyldimethylsilyl, HAL is a halogen, and R5 is an unsubstituted or substituted alkyl group or an unsubstituted or substituted aryl group.
[0074] In a fifteenth aspect of the present invention, a compound of formula I in free base form, in particular a compound obtainable according to the first aspect of the present invention or according to any one of the second to fourteenth aspects of the present invention or preferably obtained according to the first aspect of the present invention or according to any one of the second to fourteenth aspects of the present invention, is preferably reacted with a compound of formula H according to the following reaction scheme r B is converted into an acid addition salt of formula I* by reaction with an inorganic or preferably organic acid:
[0075]
[0076] H r B is an acid, wherein r is an integer, preferably 1, 2, 3 or 4.
[0077] In the sixteenth aspect of the invention, the compound of formula III is preferably obtained by halogenating the compound of formula XVIII with a halogenating agent, such as a halogenated succinamide, such as bromosuccinimide, preferably in an aprotic solvent such as a halogenated hydrocarbon, a nitrile, an ether or a C1-C6 alkanoyl-di(C1-C6 alkyl)amide, such as acetonitrile, dichloromethane, tetrahydrofuran or N,N-dimethylacetamide, or a mixture of two or more of these solvents, preferably at a temperature in the range of 10°C to the boiling point of the reaction mixture, for example from 10°C to 100°C,
[0078]
[0079] wherein LG is a leaving group, especially a halogen such as chlorine, to give a compound of formula XIX:
[0080]
[0081] wherein LG is a leaving group, especially as defined above, and Hal is halogen, especially bromine, followed by substitution with a mercapto compound of formula XX:
[0082] R6O-C(=O)-CH2-CH2-SH (XX);
[0083] wherein R6 is unsubstituted or substituted alkyl or unsubstituted or substituted aryl, especially C1-C6 alkyl such as ethyl, to obtain a compound of formula XXI,
[0084]
[0085] Wherein LG is a leaving group, and R6 is an unsubstituted or substituted alkyl or an unsubstituted or substituted aryl (both preferably as defined above). The reaction is preferably carried out in the presence of a noble metal complex comprising a noble metal, especially palladium and a ligand such as Xantphos, in the presence of a tertiary amine such as diisopropylethylamine, in an aprotic solvent such as an ester, preferably a cyclic ester such as dioxane. The reaction is carried out at a preferably elevated temperature (e.g. from 30° C. to the boiling point of the reaction mixture). The compound of formula XXI is then treated with an alkali metal, especially a methoxylate or ethoxylate of lithium, potassium or most especially sodium to obtain a compound of formula XXII:
[0086]
[0087] Wherein Mt is an alkali metal, in particular as just defined, a compound of formula XXII is then reacted with a compound of formula XXIII. The reaction is preferably carried out in a solvent such as an alcohol, for example methanol or ethanol (in particular an alcohol matched to the alkoxylate so that the alkoxy group is the same as the organic residue in the alcohol), and a mixture of an ether, for example a cyclic ether such as tetrahydrofuran, preferably at a temperature ranging from about 0°C to about 50°C:
[0088]
[0089] To obtain the compound having formula III:
[0090]
[0091] wherein LG is a leaving group, in particular as defined above for the compound of formula III.
[0092] The compound of formula XXIII may preferably be prepared by making a compound of formula XXIV:
[0093]
[0094] With iodine in the presence of a strong base, especially an alkyl-alkali metal, such as n-butyllithium, and a nitrogen base, especially diisopropylamine or diethylamine, in a solvent such as an acyclic or especially cyclic ether, preferably tetrahydrofuran, at preferably low temperatures, for example, in the range of about -80°C to about -5°C.
[0095] and treating the resulting compound of formula XXV with ammonia,
[0096]
[0097] The reaction is then preferably carried out in the presence of gaseous ammonia and an inert polar solvent such as DMSO, especially at elevated temperature, preferably in the range of from about 30°C to the boiling point of the reaction mixture, for example at about 85°C to about 95°C.
[0098] As an alternative to the synthesis from compounds of formula XVIII, it is also possible to synthesize from compounds of formula XXVI by treating them with ammonia:
[0099]
[0100] to obtain a compound of formula XIX, wherein Hal is chloro (reaction conditions are preferably as just described for the reaction of a compound of formula XXV) to obtain a compound of formula XIX, wherein Hal is chloro and LG is chloro, then via further reaction of a compound of formula XXI, XXII, then reacting as above with a compound of formula XXIII (preferably obtained as described above) to obtain a compound of formula III, each compound and reaction conditions preferably as preferably defined above.
[0101] In a seventeenth aspect, the compound of formula XXVI just described can be reacted with ammonia (preferably in aqueous medium and at a temperature ranging from about 0°C to about 80°C) to obtain a compound of formula XIX, wherein Hal is chlorine and LG is chlorine, and then the compound of formula XIX is reacted with a (preferably anhydrous) alkali metal sulfide of formula Mt2S, wherein Mt is an alkali metal, especially sodium, and then post-treated with a quaternary ammonium halide of formula (alk)4NZ, wherein each alk is independently an alkyl, especially n-alkyl, such as C1-C6-alkyl, and Z is halogen, especially chlorine or more especially bromine, to obtain a compound of formula XXVII,
[0102]
[0103] wherein alk is as just defined, can then be reacted with a compound of formula XXIII (which can preferably be prepared as described above), preferably in the presence of a copper(I) iodide complex such as CuI / phenanthroline, in a suitable solvent, for example in water or an alcohol or a mixture thereof, preferably in water and / or methanol, ethanol or especially isopropanol, preferably at a temperature ranging from about -20°C to about 80°C, for example from about 0 to about 40°C, to give a compound of formula III. BRIEF DESCRIPTION OF THE DRAWINGS
[0104] Figure 1 : Figure 1 (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decane-4-amine succinate (1:1) hemihydrate variant (form) H is shown A XRPD.
[0105] Figure 2 : Shown is the XRPD of (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine hydrochloride.
[0106] Figure 3: Shown is the XRPD of (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine methanesulfonate.
[0107] Figure 4 : Shown is the XRPD of (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine fumarate.
[0108] Figure 5 : XRPD of (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decane-4-amine adipate (1:1) modification A is shown.
[0109] Figure 6 : XRPD of (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decane-4-amine succinate (1:1) anhydrous Form Modification A is shown.
[0110] Figure 7 : (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decane-4-amine succinate (2:1) hydrate variant H is shown A XRPD.
[0111] Figure 8 : XRPD diagram showing (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decane-4-amine succinate (2:1) anhydrate variant A
[0112] Fig. 9 : XRPD of (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine free base variation A is shown.
[0113] Fig.10: (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decane-4-amine succinate (2:1) hydrate variant H is shown B XRPD.
[0114] definition
[0115] "SHP2" means "Src homology region-2 phosphatase", and is also known as SH-PTP2, SH-PTP3, Syp, PTP1D, PTP2C, SAP-2 or PTPN11. Cancers carrying "PTPN11 mutations" include, but are not limited to: N58Y; D61Y, V; E69K; A72V, T, D; E76G, Q, K (ALL); G60A; D61Y; E69V; F71K; A72V; T73I; E76G, K; R289G; G503V (AML); G60R, D61Y, V, N; Y62D; E69K; A72T, V; T73 I; E76K,V,G,A,Q; E139D; G503A,R; Q506P (JMML); G60V; D61V; E69K; F71L; A72V; E76A (MDS); Y63C (CMML); Y62C; E69K; T507K (neuroblastoma); V46L; N58S; E76V (lung cancer); R138Q (melanoma); E76G (colon cancer).
[0116] The present invention also includes all suitable isotopic variations of the compounds mentioned in the above methods and especially in the above Examples A to K. An isotopic variation is defined as an isotopic variation in which at least one atom is replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found in nature. Examples of isotopes that can be incorporated include, but are not limited to, isotopes of hydrogen, carbon, nitrogen and oxygen, such as 2 H. 3 H. 11 C. 13 C. 14 C. 15 N. 17 O. 18 O. 35 S. 18 F. 36 Cl and 123 I. Certain isotopic variants, for example those in which radioactive isotopes such as 3 H or 14 C, can be used for drug and / or substrate tissue distribution studies. In a specific example, 3 H and 14C isotope to facilitate its preparation and detection. In other examples, for example, 2 Substitution with isotopes of H may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements. Isotopic variations can generally be prepared by conventional procedures using appropriate isotopic variations of suitable reagents. DETAILED DESCRIPTION
[0117] The following definitions define more general features in a preferred more specific manner and it is possible to replace one, more than one or all of the more general features of the inventive variants=embodiments with more specific definitions defining more specific inventive embodiments. This also applies to the above-mentioned reaction embodiments and their preferred forms as described above.
[0118] The compounds mentioned may be present in free form or as their salts, in which salt-forming groups (e.g. imino or amino groups) are present, in particular acid addition salts, such as salts with inorganic acids, such as hydrogen halides, for example HCl, sulfuric acid or phosphoric acid; and / or salts with organic acids, such as sulfonic acids, for example methanesulfonic acid, ethylsulfonic acid or toluenesulfonic acid, phosphonic acids or carboxylic acids, for example alkanoic acids, such as acetic acid or citric acid.
[0119] In the following, preferred conditions for the above reaction are defined:
[0120] The reaction of compound II with a compound of formula III (reaction h) wherein LG is a leaving group, preferably a halogen, especially chlorine or bromine, is preferably carried out in the presence of a weak base, such as an alkali metal carbonate or bicarbonate, preferably in an aprotic solvent, such as an N,N-dialkylamide of an alkanoic acid, for example dimethylacetamide or dimethylformamide, preferably at elevated temperature, for example at a temperature ranging from about 30°C to about the boiling point of the reaction mixture, for example from about 50°C to about 100°C.
[0121] The reaction of a compound of formula IV to give a compound of formula II (reaction i) is preferably carried out in a reaction mixture of a compound of formula H as defined above and below. n The reaction is carried out in the presence of a (achiral) organic or preferably inorganic acid of A, preferably trifluoroacetic acid, trifluoromethanesulfonic acid, or preferably an inorganic acid, for example sulfuric acid, phosphoric acid or in particular a hydrogen halide, most especially hydrogen chloride, preferably in a solvent, for example an alcohol or a mixture of alcohols, such as isopropanol and / or methanol, and / or in the presence of water (especially if R2 is acyl, especially lower alkanoyl, such as acetyl), at a preferred temperature in the range from about 0°C to about the boiling point of the solvent, for example from about 10°C to (especially in the case of R2 is acyl) about 40°C.
[0122] The reaction of a compound of formula V with a chiral acid HY to give a compound of formula IV (reaction j) is preferably carried out in the presence of a nonpolar, especially aprotic solvent such as a nitrile, for example acetonitrile, preferably at a temperature ranging from about 10° C. to about the boiling point of the reaction mixture, for example from about 15° C. to about 75° C. The chiral acid HY is preferably a chiral carboxylic acid or a sulfonic acid or a phosphonic acid, especially a chiral carboxylic acid having one carboxylic acid (—COOH) group, for example (—)-O-acetyl-D-mandelic acid, dibenzyl-D-tartaric acid, or di-p-toluoyl-D-tartaric acid. R1 is preferably C1-C6 alkoxycarbonyl, for example tert-butoxycarbonyl, and A is preferably an anion of an acid, especially an anion of an acid mentioned in the paragraph just preceding this paragraph.
[0123] The reaction of the compound of formula VI to give the compound of formula V (reaction k) is preferably carried out in the presence of an acid, especially a strong acid, for example an inorganic acid, such as sulfuric acid, phosphoric acid or especially a hydrohalic acid, preferably hydrochloric acid, preferably in a solvent, for example an alcohol, such as an alkanol, for example methanol, ethanol or especially isopropanol, or an ester, such as an alkylalkanoate, for example isopropyl acetate or a mixture thereof, in the presence or absence of water, at a preferred temperature in the range from -50°C to 30°C, for example at a temperature from -30°C to 10°C, to give the compound of formula V in the form of a salt of the acid, which is then preferably converted into the free base of the compound of formula V by reaction with a base, for example an alkali metal hydroxide, such as LiOH, KOH or especially NaOH, preferably in an organic solvent, for example in an ether, such as methyl tert-butyl ether, preferably at low temperature, for example at a temperature in the range from -50°C to 10°C, in particular from -20°C to 0°C. R1 is preferably a C1-C6 alkoxycarbonyl group, such as tert-butoxycarbonyl, and R2 is preferably a tert-C4-C6 alkyl group, such as tert-butyl.
[0124] The reduction of the compound of formula VII to give the compound of formula VI (reaction 1) is preferably carried out with a complex hydride capable of reducing the imino group, such as lithium borohydride, preferably in an organic solvent, for example, in a mixture of alcohols (for example propanol, ethanol or especially methanol) and / or ethers (especially cyclic ethers such as tetrahydrofuran), preferably at low temperatures, for example at a temperature ranging from about -78°C to about 0°C, especially from about -50°C to about -20°C. R1 and R2 are preferably as defined in the paragraph immediately preceding this paragraph.
[0125] The reaction of a compound of formula VIII with a compound of formula IX to give a compound of formula VII (reaction m) is preferably carried out in the presence of a Lewis acid which activates the carbonyl group for condensation, such as titanium tetraisopropionate or especially titanium tetraethoxide, preferably in an aprotic solvent, for example in an ether, such as a cyclic ether, especially tetrahydrofuran, at a preferred temperature in the range from about 20° C. to about the boiling point of the reaction mixture, for example from about 40° C. to about 80° C. R1 and R2 are preferably as defined in the two paragraphs immediately preceding this paragraph.
[0126] The oxidation of the compound of formula X to give the compound of formula VIII (reaction n) is preferably carried out in the presence of an oxidizing agent such as a mixture of TEMPO ((2,2,6,6-tetramethylpiperidin-1-yl)oxy) and a bleach (especially sodium hypochlorite or potassium hypochlorite, Javert solution), TEMPO and (diacetoxy)iodobenzene or preferably Dess-Martin reagent, preferably in an aprotic solvent, for example in a halogenated hydrocarbon, such as dichloromethane, preferably at a temperature ranging from about -40°C to about 40°C, for example from about -10°C to about 30°C. R1 is preferably C1-C6 alkoxycarbonyl, such as tert-butoxycarbonyl.
[0127] The cyclization of the compound of formula XI to give the compound of formula X (reaction o) is preferably carried out in the presence of a phase transfer catalyst, for example a tetraalkylammonium halide, such as tetra-n-butylammonium bromide, preferably in an aprotic solvent, such as an ether, especially a cyclic ether, such as tetrahydrofuran, at a preferred temperature ranging from about -20°C to about 50°C, for example from about -5 to about 30°C. R1 is preferably C1-C6 alkoxycarbonyl, such as tert-butoxycarbonyl, R2 is preferably tert-C4-C6 alkyl, such as tert-butyl, Pr1O is preferably alkoxy or preferably perfluoroalkylsulfonyloxy, tosyloxy or methanesulfonyloxy, and Pr2 is preferably a trialkyl- or diphenylalkyl-silyl group, preferably a trialkylsilyl group, more preferably a trimethylsilyl group, tert-butyldiphenylsilyl, triisopropylsilyl or especially tert-butyldimethylsilyl.
[0128] Protection of a compound of formula XII with a compound of formula Pr1H to give a compound of formula XI (reaction p) is preferably carried out in the presence of a base, such as an alkali metal bis(trialkyl-substituted silyl)amide, such as lithium bis(trimethylsilyl)amide, preferably in an aprotic solvent, such as an ether, for example a cyclic ether, such as tetrahydrofuran, at a preferred temperature in the range from about -50°C to about 50°C, for example from about -10°C to about 10°C. R1 is preferably C1-C6 alkoxycarbonyl, such as tert-butyloxycarbonyl, Pr1 is preferably alkyl or preferably perfluoroalkylsulfonyl, tosyl or methylsulfonyl, and Pr2 is preferably a trialkyl- or diphenylalkyl-silyl group, preferably a trialkylsilyl group, more preferably a trimethylsilyl group, more preferably a trimethylsilyl, tert-butyldiphenylsilyl, triisopropylsilyl or especially tert-butyldimethylsilyl group.
[0129] The reduction of the compound of formula XIII to the compound of formula XII (reaction q) is preferably carried out with a complex hydride capable of reducing the esterified carboxyl group to a hydroxymethyl group, such as lithium aluminum hydride, Red-Al (sodium-bis(2-methoxyethoxy)aluminum hydride), sodium borohydride, in the presence of calcium chloride or especially lithium borohydride, preferably in an aprotic solvent, such as an ether, such as a cyclic ether, such as tetrahydrofuran, preferably at a temperature ranging from about -50°C to about 50°C, such as from about 10°C to about 40°C. R1 is preferably C1-C6 alkoxycarbonyl, such as tert-butyloxycarbonyl, Ra is preferably alkyl, more preferably C1-C6 alkyl, such as ethyl, and Pr2 is preferably a trialkyl- or diphenylalkyl-silyl group, preferably a trialkylsilyl group, more preferably trimethylsilyl, tert-butyldiphenylsilyl, triisopropylsilyl or especially tert-butyldimethylsilyl.
[0130] The reaction of a compound of formula XIV with a compound of formula XV to give a compound of formula XIII (reaction r) is preferably carried out in the presence of a strong base, such as lithium bis(trimethylsilyl)amide, lithium 2,2,6,6-tetramethylpiperidinium or especially lithium diisopropylamide, preferably in an aprotic solvent, preferably an ether, such as a cyclic ether, especially tetrahydrofuran, preferably at low temperatures, for example, at a temperature ranging from about -78°C to about 0°C, for example from about -60°C to about -18°C. R1 is preferably C1-C6 alkoxycarbonyl, such as tert-butyloxycarbonyl, Ra is preferably alkyl, more preferably C1-C6 alkyl, for example ethyl, and Pr2 is preferably a trialkyl- or diphenylalkyl-silyl group, preferably a trialkylsilyl group, more preferably trimethylsilyl, tert-butyldiphenylsilyl, triisopropylsilyl or especially tert-butyldimethylsilyl.
[0131] Reacting a compound of formula XVI to give a compound of formula XIV (reaction s) is preferably carried out in the presence of a reducing agent capable of reducing the hydroxyamide group to a carbonyl group, such as Red-Al or in particular lithium aluminum hydride, preferably in an aprotic solvent, such as an ether and / or a halogenated hydrocarbon, such as a cyclic ether and / or a halogenated alkane, such as tetrahydrofuran and / or dichloromethane, preferably at low temperature, for example at a temperature of from about -100°C to about 0°C, such as from about -78°C to about -50°C. Pr2 is preferably a trialkylsilyl group, more preferably trimethylsilyl, tert-butyldiphenylsilyl, triisopropylsilyl or especially tert-butyldimethylsilyl, and R3 and R4 are each preferably an alkyl group, more especially methyl or ethyl, and Pr2 is preferably a trialkyl- or diphenylalkyl-silyl group, preferably a trialkylsilyl group, more preferably trimethylsilyl, tert-butyldiphenylsilyl, triisopropylsilyl or especially tert-butyldimethylsilyl.
[0132] The reaction of the compound of formula XVII to give the compound of formula XVI (reaction t) is preferably carried out with a hydroxylamine compound of formula R3-O-NH-R4, wherein R3 and R4 are as defined above for the compound of formula XVI:
[0133]
[0134] Wherein, Pr2 is a substituted silyl protecting group, R3 is an alkyl group, R4 is an alkyl group, and R5 is an unsubstituted or substituted alkyl group or an unsubstituted or substituted aryl group. The reaction is preferably carried out in the presence of a Grignard reagent, preferably a Grignard reagent having the formula Org-MgX, wherein Org is a hydrocarbon group, especially a hydrocarbon group having up to 10 carbon atoms, especially isopropylmagnesium chloride. Preferably, the reaction is carried out at a temperature ranging from about -50°C to about 50°C, for example, ranging from about -20°C to about 20°C. R3 and R4 are each independently of one another preferably C1-C6 alkyl, for example ethyl or especially methyl, and Pr2 is preferably a trialkylsilyl group, more preferably trimethylsilyl, tert-butyldiphenylsilyl, triisopropylsilyl or especially tert-butyldimethylsilyl.
[0135] Protection of a compound of formula XVIII with a compound of formula PrHAL to give a compound of formula XVII (reaction u) is preferably carried out in the presence of a tertiary nitrogen base such as imidazole, preferably in an aprotic solvent such as a halogenated hydrocarbon, especially dichloromethane, at a preferred temperature ranging from about -50°C to about 50°C, especially from about -20°C to about 20°C.
[0136] Preferably, R5 is phenyl-C1-C6-alkyl or especially C1-C6-alkyl; Pr2 is trimethylsilyl, tert-butyl-diphenylsilyl, triisopropylsilyl or especially tert-butyldimethylsilyl. HAL is preferably bromine or especially chlorine.
[0137] The compound of formula I and the acid H r The reaction of the compound of formula I* (actually a salt) with H (preferably an inorganic acid, for example a hydrohalic acid (r=2), such as hydrochloric acid, sulfuric acid (r=2) or phosphoric acid (r=3), or in particular an organic acid, for example methanesulfonic acid or adipic acid (r=1), or in particular dicarbonic acid (r=2), preferably fumaric acid, most preferably succinic acid) is preferably carried out in acetonitrile, water and / or one or more alcohols, such as (optionally aqueous in each case) methanol, ethanol or isopropanol (or a mixture of 2 or 3 thereof) or acetonitrile. The reaction is carried out at a preferred temperature of from -40°C to the boiling point of the reaction mixture, preferably at a temperature of from 30°C to 80°C, preferably followed by cooling, for example from about -30°C to about 30°C. Alternatively, the salt can be prepared in the presence of an acid H. r It is obtained from a suspension of a compound of formula I in the presence of B at a temperature ranging from about 20°C to about 70°C, preferably in an organic solvent such as an ether, for example tetrahydrofuran. r B is preferably as described above for a compound having the formula H n The acid of A is defined as an acid, or more particularly selected from the group consisting of succinic acid, hydrochloric acid, methanesulfonic acid, fumaric acid and adipic acid. Succinic acid is preferred.
[0138] Preferably, each salt of formula I* can be obtained by seeding with the corresponding salt obtained as described in Examples 6-14 below.
[0139] The present invention also relates to the following embodiments:
[0140] Example A: The present invention also relates to compounds or more precisely salts, especially salts in crystalline form, having formula I*:
[0141]
[0142] Among them, H r B is an acid selected from the group consisting of succinic acid, hydrochloric acid, methanesulfonic acid, fumaric acid and adipic acid. Succinic acid is preferred.
[0143] The free base ratio of the divalent acid is preferably in the following range: (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine:acid (mol:mol) = 1:1 to 1:1.5, or can be 2:1. In the following, the compounds of formula I* are basically named by naming the anion of the acid (e.g. succinate), and the brackets indicate (approximately, e.g. ±40%, more preferably the corresponding first ±35%) stoichiometry of the binary value, for example (1:1) means 1 molecule of acid (e.g. succinic acid) per 1 (±40%, preferably ±35%) molecule of (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine ("free base"), or for example (2:1) means 2 molecules of acid per 1 (±40%, preferably ±35%) molecule of "free base", for example in the case of hemisuccinate.
[0144] When referring to compounds of formula I*, this may relate to salts or co-crystal forms which may occasionally not be distinguishable from true salts by some of the characterization methods indicated below, but which can be distinguished from true salts, for example, by NMR spectroscopy. Preference is given to salts.
[0145] Embodiment B: More preferably, the compound having formula I* is (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decane-4-amine (whose free form is a compound having formula I) succinate.
[0146] Example C: Most preferably, the present invention relates to (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decane-4-amine succinate (1:1) hemihydrate Form H A (falling within formula I*), especially characterized by XRPD (X-ray powder diffraction pattern) having at least one, two, three or all of the following 2-theta values: 8.1, 16.3, 17.5, 22.5 and 26.8.
[0147] More preferably, the XRPD shows the 2-theta peaks indicated in the table of 2-theta values in Example 6, and still more preferably the XRPD is as follows: Figure 1 as shown in .
[0148] Also preferred is (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decane-4-amine succinate (1:1) hemihydrate Form H A (falling into formula I*), which has a melting point onset of 186° C. in differential scanning calorimetry (DSC), which feature can be used alone or in combination with the XRPD data just mentioned.
[0149] Example D: The present invention also relates to (3S, 4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine hydrochloride (falling into formula I*), especially having one, two, three, four or more or all of the XRPD peaks shown in the 2-θ table of Example 7, especially having the following: Figure 2 XRPD pattern shown.
[0150] Example E: The present invention also relates to (3S, 4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine methanesulfonate (falling into Formula I*), especially having one, two, three, four or more or all of the XRPD peaks shown in the 2-θ table of Example 8, especially having the following: Figure 3 XRPD pattern shown.
[0151] Example F: The present invention also relates to (3S, 4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decane-4-amine fumarate (falling into Formula I*), especially having one, two, three, four or more or all of the XRPD peaks shown in the 2-θ table of Example 9, especially having the following: Figure 4 XRPD pattern shown.
[0152] Example G: The present invention also relates to (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decane-4-amine adipate (falling into formula I*), preferably the latter can be characterized by 1, 2, 3 or more or preferably all XRPD peaks having 2-θ values as shown in the 2-θ table in Example 10, especially as Figure 5 or a melting onset temperature at 145.3° C. in the DSC, or any combination of these features.
[0153] Example H: The present invention also relates to (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decane-4-amine succinate (1:1) anhydrate modification A (falling within formula I*), preferably characterized by having 2-θ values of 14.8, 19.2, 19.7, 22.3, 24.8, 25.8 or 1, 2, 3 or more XRPD or preferably all peaks as shown in the 2-θ table in Example 11, especially as Figure 6 The XRPD pattern shown, or a melting onset at 175.5°C in DSC, or any combination of these features.
[0154] Example I: The present invention also relates to (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decane-4-amine succinate (2:1) hydrate variant H A (falling within formula I*), preferably characterized by having 2-theta values of 11.5, 19.1, 22.0, 23.7, 24.9° or 1, 2, 3 or preferably all XRPD peaks with 2-theta values as shown in the 2-theta table in Example 12, especially as Figure 7 The XRPD pattern shown, or a melting onset at 167.9°C in DSC, or any combination of these features.
[0155] Example J: The present invention also relates to (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decane-4-amine succinate (2:1) anhydrate modification A (falling within formula I*), preferably characterized by having 2-θ values of 4.9, 13.3, 16.4, 17.0, 19.6, 20.6, 23.5° or 1, 2, 3 or preferably all peaks of 2-θ values as shown in the 2-θ table in Example 14, especially as Figure 8 The XRPD pattern shown, or a melting onset at 174.0°C in DSC, or any combination of these features.
[0156] Example K: The present invention also relates to (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine free base, in particular modification A thereof, preferably the latter may be characterized by 1, 2, 3 or more or preferably all XRPD peaks having 2-θ values as shown in the 2-θ table in Example 13, in particular as Fig. 9The XRPD pattern shown, or a melting onset temperature at 145.3°C in DSC, or any combination of these features.
[0157] Example L: The present invention also relates to (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decane-4-amine succinate (2:1) hydrate variant H B (falling within Formula I*), preferably characterized by having 1, 2, 3 or more XRPD peaks with 2-theta values of 4.8, 12.1, 16.4, 17.0, 19.6, 20.6, 23.6° or 2-theta values as shown in the 2-theta table in Example 15, especially having Fig.10 The XRPD pattern shown, or a DSC onset temperature at 171.7°C, or any combination of these features.
[0158] Note that in each case where 2-θ values are given (also in the examples), they mean (in order to compensate for measurement errors) ° 2θ ± 0,5 ° 2θ, more preferably ± 0,2 ° 2θ of the corresponding value. When 1, 2, 3 or more XRPD peaks are mentioned, it is most preferred to have the form with all mentioned peaks.
[0159] The present invention also relates to the following pharmaceutical composition, which comprises: a compound having formula I*, and at least one pharmaceutically acceptable excipient,
[0160]
[0161] Among them, H r B is an acid selected from the group consisting of succinic acid (most preferred), hydrochloric acid, methanesulfonic acid, fumaric acid and adipic acid, more preferably a salt or salt form as mentioned in any one of the above Examples A to K, most preferably (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine monosuccinate hydrate form H, especially as defined in Example C above. A .
[0162] The present invention also relates to a method for treating a disease in an animal, especially a human, in which modulation of SHP2 activity can prevent, inhibit or ameliorate the pathology and / or symptomology of the disease, the method comprising administering to an animal, especially an animal in need thereof, a therapeutically effective amount of a salt as described in the preceding paragraph, alone or in combination simultaneously or sequentially with another anti-cancer therapeutic agent.
[0163] The present invention also relates to a salt or salt form as described in any one of Examples A to K above for use in a method of treating a disease in an animal in which SHP2 activity can prevent, inhibit or ameliorate the pathology and / or symptomology of the disease, the method comprising administering the salt or salt form to a warm-blooded animal, especially a human patient.
[0164] The present invention also relates to the use of a salt or salt form as described in any one of Examples A to K above in the manufacture of a medicament for treating a disease in an animal, especially a human patient, wherein SHP activity contributes to the pathology and / or symptomology of the disease.
[0165] In all embodiments, the succinate hydrate form H A is the most preferred salt form for use in practice.
[0166] In one embodiment is a method of making a compound of formula I or a pharmaceutically acceptable salt, acid cocrystal, hydrate or other solvate thereof, the method comprising: reacting a compound of formula II with a compound of formula III according to the following reaction scheme:
[0167]
[0168] wherein A is the anion of the acid, LG is a leaving group, and n and m are integers selected from 1, 2 or 3 such that the compound of Formula II is uncharged.
[0169] In another embodiment, the method of the present invention further comprises reacting a compound having formula IV with a compound having formula H n The acid of A is reacted according to the following reaction scheme to give a compound having formula II:
[0170]
[0171] wherein R1 is a protecting group for a secondary amino group, HY is a chiral acid, A is an anion of the acid, and n and m are integers selected from 1, 2 or 3, such that the compound of formula II is uncharged.
[0172] In another embodiment, the method further comprises reacting the compound of formula V or a salt thereof with a chiral acid of formula HY according to the following reaction scheme to obtain a compound of formula IV:
[0173]
[0174] wherein R1 is a protecting group and HY is a chiral acid.
[0175] In another embodiment, the method further comprises reacting a compound having formula VI to obtain a compound having formula V according to the following reaction scheme:
[0176]
[0177] wherein R1 is a protecting group, and *R2 is an alkyl group.
[0178] In another embodiment, the method comprises reducing a compound having formula VII to obtain a compound having formula VI according to the following reaction scheme:
[0179]
[0180] wherein R1 is a protecting group, and *R2 is an alkyl group.
[0181] In another embodiment, the method of the present invention comprises reacting a compound having formula VIII with a compound having formula IX to obtain a compound having formula VII:
[0182]
[0183] wherein R1 is a protecting group, and *R2 is an alkyl group.
[0184] In another embodiment, the method further comprises oxidizing the compound of formula X to obtain a compound of formula VIII according to the following reaction scheme:
[0185]
[0186] Wherein R1 is a protecting group.
[0187] In another embodiment, the method further comprises cyclizing the compound of formula XI to obtain the compound of formula X according to the following reaction scheme:
[0188]
[0189] wherein R1 is a protecting group, Pr1O is a leaving group, and Pr2 is a substituted silyl protecting group.
[0190] In another embodiment, the method of the present invention comprises protecting a compound having formula XII with a compound having formula Pr1H to obtain a compound having formula XI according to the following reaction scheme:
[0191]
[0192] wherein R1 is a protecting group, Pr1O is a leaving group, and Pr2 is a substituted silyl protecting group.
[0193] In another embodiment, the method further comprises reducing the compound having formula XIII to obtain the compound having formula XII according to the following reaction scheme:
[0194]
[0195] wherein R1 is a protecting group, Ra is an unsubstituted or substituted alkyl group or an unsubstituted or substituted aryl group, and Pr2 is a substituted silyl protecting group.
[0196] In another embodiment, the method of the present invention further comprises reacting a compound having formula XIV with a compound having formula XV to obtain a compound having formula XIII:
[0197]
[0198] wherein R1 is a protecting group, Ra is an unsubstituted or substituted alkyl group or an unsubstituted or substituted aryl group, and Pr2 is a substituted silyl protecting group.
[0199] In another embodiment, the method further comprises reducing the compound of formula XVI to obtain the compound of formula XIV according to the following reaction scheme:
[0200]
[0201] wherein Pr2 is a substituted silyl protecting group, R3 is an alkyl group, and R4 is an alkyl group.
[0202] In another embodiment, the method of the present invention further comprises reacting an ester compound having formula XVII with a compound having formula R4ONHR3 according to the following reaction scheme to obtain a compound having formula XVI:
[0203]
[0204] wherein Pr2 is a substituted silyl protecting group, R3 is an alkyl group, R4 is an alkyl group, and R5 is an unsubstituted or substituted alkyl group or an unsubstituted or substituted aryl group.
[0205] In another embodiment, the method of the present invention further comprises protecting the compound having formula XVIII with a compound having formula Pr2HAL to obtain a compound having formula XVII according to the following reaction scheme:
[0206]
[0207] wherein Pr2 is a substituted silyl protecting group, HAL is a halogen, and R5 is an unsubstituted or substituted alkyl group or an unsubstituted or substituted aryl group.
[0208] In another embodiment is a method comprising using a compound having the formula H according to the following reaction scheme: r The compound of formula I in salt form or free base form is converted into an acid addition salt of formula I* by an inorganic or organic acid of B:
[0209]
[0210] In another embodiment is a method of making a compound of formula III as defined in claim 1, the method comprising: halogenating a compound of formula XVIII with a halogenating agent:
[0211]
[0212] wherein LG is a leaving group to give a compound having the formula XIX:
[0213]
[0214] wherein LG is a leaving group and Hal is a halogen, and then substituted with a thiol compound having the formula XX,
[0215] R6O-C(=O)-CH2-CH2-SH (XX)
[0216] wherein R6 is unsubstituted or substituted alkyl or unsubstituted or substituted aryl, to give a compound of formula XXI,
[0217]
[0218] wherein LG is a leaving group, and R6 is an unsubstituted or substituted alkyl or an unsubstituted or substituted aryl; and then treating the compound of formula XXI with an alkali metal alkoxide to obtain a compound of formula XXII,
[0219]
[0220] wherein Mt is an alkali metal, then reacting a compound having formula XXII with a compound having formula XXIII:
[0221]
[0222] To obtain the compound having formula III:
[0223]
[0224] Where LG is a leaving group.
[0225] In another embodiment is a method of making a compound having Formula XXIII:
[0226]
[0227] The method comprises subjecting a compound having formula XXIV to
[0228]
[0229] reacting with iodine in the presence of a strong base; and treating the resulting compound of formula XXV,
[0230]
[0231] To obtain a compound having formula XXIII.
[0232] In another embodiment is a compound having Formula I*:
[0233]
[0234] Among them, H r B is an acid selected from the group consisting of succinic acid, hydrochloric acid, methanesulfonic acid, fumaric acid and adipic acid, and at least one pharmaceutically acceptable carrier.
[0235] In yet another embodiment, the compound is in crystalline form.
[0236] In another embodiment is (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine monosuccinate free base in crystalline form.
[0237] In another embodiment, (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decane-4-amine succinate (1:1) hydrated form H A .
[0238] In another embodiment, S (3S, 4S) -8- (6-amino-5- ( (2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) -3-methyl-2-oxa-8-azaspiro [4.5] decan-4-amine hydrochloride. In yet another embodiment, the compound is in crystalline form.
[0239] In another embodiment is (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine methanesulfonate. In yet another embodiment, the compound is in crystalline form.
[0240] In another embodiment is (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine fumarate. In yet another embodiment, the compound is in crystalline form.
[0241] In another embodiment is (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decane-4-amine adipate. In yet another embodiment, the compound is in crystalline form.
[0242] In another embodiment is (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decane-4-amine succinate (1:1) anhydrous form.
[0243] In another embodiment is (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine succinate (2:1) hydrate.
[0244] In another embodiment is (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine succinate (2:1) anhydrate.
[0245] In another embodiment is a pharmaceutical composition comprising a compound having formula I* according to any one of the above embodiments.
[0246] In another embodiment, the compound of formula I* is (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decane-4-amine succinate (1:1) hydrated form H A .
[0247] In another embodiment is a method of treatment comprising administering to a patient in need of such treatment an effective amount of a compound having formula I* as defined in any one of claims 18 to 32 for the prophylactic or therapeutic treatment of a disease or disorder mediated by SHP2 activity.
[0248] In another embodiment, the method of claim 35, wherein the disease or disorder mediated by SHP2 activity is selected from Noonan syndrome, Leopard syndrome, juvenile myelomonocytic leukemia, neuroblastoma, melanoma, acute myeloid leukemia, breast cancer, esophageal cancer, lung cancer, colon cancer, head cancer, neuroblastoma, head and neck squamous cell carcinoma, gastric cancer, anaplastic large cell lymphoma and glioblastoma.
[0249] In another embodiment is a combination comprising a compound of formula I* as defined in any one of the above embodiments, and one or more other pharmacologically active compounds, in particular antiproliferative agents, for simultaneous, sequential or separate administration.
[0250] Pharmacology and efficacy
[0251] Src homology region-2 phosphatase (SHP2) is a protein tyrosine phosphatase encoded by the PTPN11 gene that contributes to a variety of cellular functions, including proliferation, differentiation, cell cycle maintenance, and migration. SHP2 is involved in signal transduction through the Ras-mitogen-activated protein kinase, JAK-STAT, or phosphoinositide 3-kinase-AKT pathways. SHP2 mediates the activation of Erk1 and Erk2 (Erk1 / 2, Erk) MAP kinases through receptor tyrosine kinases such as ErbB1, ErbB2, and c-Met.
[0252] SHP2 has two N-terminal Src homology region 2 domains (N-SH2 and C-SH2), a catalytic domain (PTP) and a C-terminal tail. The two SH2 domains control the subcellular localization and functional regulation of SHP2. The molecule exists in an inactive conformation and inhibits its own activity through a binding network involving residues from the N-SH2 and PTP domains. In response to growth factor stimulation, SHP2 binds to specific tyrosine phosphorylation sites on docking proteins (such as Gab1 and Gab2) through its SH2 domain. This induces conformational changes, leading to SHP2 activation.
[0253] Mutations in PTPN11 have been identified in a variety of human diseases, such as Noonan syndrome, Leopard syndrome, juvenile myelomonocytic leukemia, neuroblastoma, melanoma, acute myeloid leukemia, and breast, lung, and colon cancers. SHP2 is an important downstream signaling molecule for multiple receptor tyrosine kinases, including receptors for platelet-derived growth factor (PDGF-R), fibroblast growth factor (FGF-R), and epidermal growth factor (EGF-R). SHP2 is also an important downstream signaling molecule for activation of the mitogen-activated protein (MAP) kinase pathway, which can lead to cellular transformation, a prerequisite for cancer development. Knockdown of SHP2 significantly inhibited cell growth in lung cancer cell lines with SHP2 mutations or EML4 / ALK translocations, as well as EGFR-amplified breast and esophageal cancers. SHP2 is also activated downstream of oncogenes in gastric cancer, anaplastic large cell lymphoma, and glioblastoma.
[0254] Noonan syndrome (NS) and Leopard syndrome (LS) - PTPN11 mutations cause LS (multiple lentigenes, ECG conduction abnormalities, hypertelorism, pulmonary stenosis, genital anomalies, growth retardation, sensorineural deafness) and NS (congenital anomalies including heart defects, craniofacial malformations, and short stature). Both disorders are part of a family of autosomal dominant syndromes caused by germline mutations in components of the RAS / RAF / MEK / ERK mitogen-activated protein kinase pathway required for normal cell growth and differentiation. Dysregulation of this pathway has profound effects, particularly on cardiac development, leading to a variety of abnormalities, including valvular septal defects and / or hypertrophic cardiomyopathy (HCM). Perturbations in the MAPK signaling pathway have been identified as critical for these disorders, and several candidate genes along this pathway have been identified in humans, including mutations in KRAS, NRAS, SOS1, RAF1, BRAF, MEK1, MEK2, SHOC2, and CBL. The most commonly mutated gene in NS and LS is PTPN11. Germline mutations in PTPN11 (SHP2) are found in approximately 50% of NS cases and in nearly all LS patients who share certain features with NS. For NS, Y62D and Y63C substitutions in this protein are largely invariant and are among the most common mutations. Both mutations affect a catalytically inactive conformation of SHP2 without interfering with the binding of the phosphatase to its phosphorylation signaling partner.
[0255] Somatic mutations in PTPN11 (SHP2) occur in approximately 35% of patients with JMML, a childhood myeloproliferative disorder (MPD). These gain-of-function mutations are usually point mutations in the N-SH2 domain or the phosphatase domain that prevent autoinhibition between the catalytic domain and the N-SH2 domain, resulting in SHP2 activity.
[0256] Acute Myeloid Leukemia - PTPN11 mutations have been identified in approximately 10% of pediatric acute leukemias, such as myelodysplastic syndrome (MDS); approximately 7% of B-cell acute lymphoblastic leukemia cases (B-ALL); and approximately 4% of acute myeloid leukemia (AML).
[0257] NS and leukemic mutations result in amino acid changes at the interface formed by N-SH2 and the PTP domain in an autoinhibitory SHP2 conformation, disrupting the inhibitory intramolecular interaction and leading to hyperactivity of the catalytic domain.
[0258] SHP2 acts as a positive regulator of receptor tyrosine kinase (RTK) signaling. amp , Her2 amp , FGFR amp , Met amp Cancers with translocated / activated RTKs, i.e., ALK, BCR / ABL) include esophageal cancer, breast cancer, lung cancer, colon cancer, gastric cancer, glioma, and head and neck cancer.
[0259] Esophageal cancer or oesophageal cancer is a malignant tumor of the esophagus. There are multiple subtypes, mainly squamous cell carcinoma (<50%) and adenocarcinoma. RTK expression rates are high in esophageal adenocarcinoma and squamous cell carcinoma. Therefore, the SHP2 inhibitors of the present invention can be used for innovative treatment strategies.
[0260] Breast cancer is the main type of cancer and the leading cause of death in women, where patients are resistant to existing drugs. There are four main subtypes of breast cancer, including luminal epithelial A, luminal epithelial B, Her2-like, and triple-negative / basal-like breast cancer. Triple-negative breast cancer (TNBC) is an aggressive breast cancer that lacks specific targeted therapy. Epidermal growth factor receptor I (EGFR) has become a promising target in TNBC. Inhibition of Her2 and EGFR by SHP2 may be a promising therapy in breast cancer.
[0261] Lung cancer - NSCLC is currently the leading cause of cancer-related mortality. It accounts for approximately 85% of lung cancers (mainly adenocarcinomas and squamous cell carcinomas). While cytotoxic chemotherapy remains an important part of treatment, tumors are more likely to benefit from targeted therapies based on genetic alterations such as EGFR and ALK in the tumor.
[0262] Colon cancer - Approximately 30% to 50% of colorectal tumors are known to have mutated (abnormal) KRAS, and BRAF mutations occur in 10% to 15% of colorectal cancers. In a subset of patients, whose colorectal tumors have been shown to overexpress EGFR, these patients show a favorable clinical response to anti-EGFR therapy.
[0263] Gastric cancer is one of the most common types of cancer. Abnormal expression of tyrosine kinases, as reflected by abnormal tyrosine phosphorylation in gastric cancer cells, is known in the art. Three receptor-tyrosine kinases (c-met (HGF receptor), FGF receptor 2, and erbB2 / neu) are often amplified in gastric cancer. Therefore, the disruption of different signaling pathways may contribute to the progression of different types of gastric cancer.
[0264] Neuroblastoma is a pediatric tumor of the developmental sympathetic nervous system that accounts for approximately 8% of childhood cancers. Genomic alterations in the anaplastic lymphoma kinase (ALK) gene have been postulated to contribute to the pathogenesis of neuroblastoma.
[0265] Squamous cell carcinoma of the head and neck (SCCHN). High levels of EGFR expression are associated with poor prognosis and resistance to radiotherapy in a variety of cancers, primarily squamous cell carcinoma of the head and neck (SCCHN). Blocking EGFR signaling leads to inhibition of receptor stimulation, cell proliferation, and reduces invasiveness and metastasis. Therefore, EGFR is a major target for new anticancer therapies in SCCHN.
[0266] The present invention relates to salts and salt forms of compounds capable of inhibiting SHP2 activity.
[0267] In certain embodiments, the present invention relates to the aforementioned methods and uses, wherein the SHP2-mediated disorder is a cancer selected from, but not limited to, JMML; AML; MDS; B-ALL; neuroblastoma; esophageal cancer; breast cancer; lung cancer; colon cancer; gastric cancer, head and neck cancer. Other diseases are selected from: NS; LS; JMML; AML; MDS; B-ALL; neuroblastoma; esophageal cancer; breast cancer; lung cancer; colon cancer; gastric cancer; head and neck cancer.
[0268] The SHP2 inhibitors of the present invention (especially SHP2 inhibitors of formula I*, most preferably as described in any one of the above embodiments A to K) can be usefully combined with another pharmacologically active compound, or with a combination of two or more other pharmacologically active compounds (particularly for the treatment of cancer). For example, a compound of formula (I) as defined above or a pharmaceutically acceptable salt thereof can be administered simultaneously, sequentially or separately in combination with one or more agents selected from the following antiproliferative agents, such as anticancer or chemotherapeutic agents: for example, mitotic inhibitors, such as taxanes, vinca alkaloids, paclitaxel, docetaxel, vincristine, vinblastine, vinorelbine or vinflunine, and other anticancer agents, such as cisplatin, 5-fluorouracil or 5-fluoro-2-4 (1H, 3H) -pyrimidinedione (5FU), flutamide or gemcitabine.
[0269] Such combinations may offer significant advantages, including synergistic activity in therapy.
[0270] Pharmaceutical composition
[0271] In another aspect, the present invention provides a pharmaceutically acceptable composition comprising a therapeutically effective amount of one or more salts or forms of the compounds described above (especially as described in Examples A to K above), formulated together with one or more pharmaceutically acceptable carriers (additives) and / or diluents. As described in detail below, the pharmaceutical compositions of the present invention can be specially formulated for administration in solid or liquid form, including those suitable for the following: (1) oral administration, for example, a drench (aqueous or non-aqueous solution or suspension), tablet (e.g., those for oral, sublingual and systemic absorption), pill, powder, granules, paste (application to the tongue); (2) parenteral administration, for example, by subcutaneous, intramuscular, intravenous or epidural injection (as, for example, a sterile solution or suspension, or a sustained release formulation); (3) topical administration, for example, as a cream, ointment or controlled release patch or spray applied to the skin; (4) intravaginal or rectal administration, for example, as a vaginal suppository, cream or foam; (5) sublingual administration; (6) ocular administration; (7) transdermal administration; (8) nasal administration; (9) pulmonary administration; or (10) intrathecal administration.
[0272] Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
[0273] The preparation (pharmaceutical composition) of the present invention includes those suitable for oral, nasal, local (including oral and sublingual), rectal, vaginal and / or parenteral administration. The preparation can be conveniently present in unit dosage form and can be prepared by any method known in the pharmaceutical field. The amount of active ingredient that can be combined with a carrier material to produce a single dosage form will vary depending on the host treated and the specific mode of administration. The amount of active ingredient that can be combined with a carrier material to produce a single dosage form is generally the amount of the compound that produces the therapeutic effect. Usually, within the range of one hundred percent, the range of amount is from about 0.1% to about 99% of the active ingredient, preferably from about 5% to about 70%, most preferably from about 10% to about 30%.
[0274] In general, a suitable daily dose of a compound of formula I* will be the amount of the lowest dose of the compound effective to produce a therapeutic effect. Such an effective dose will generally depend on the factors mentioned above. Typically, when used for the analgesic effect shown, oral, intravenous, intracerebroventricular and subcutaneous doses of a compound of formula I* to a patient range from about 0.0001 to about 100 mg per kg of body weight per day.
[0275] If desired, the effective daily dose of the active compound of formula I* (or any combination partner) may be administered as two, three, four, five, six or more sub-doses at appropriate intervals throughout the day, optionally in unit dosage form. The preferred dose is administered once a day.
[0276] In certain embodiments, the formulations of the invention comprise an excipient selected from the group consisting of cyclodextrins, celluloses, liposomes, micelle formers (e.g., bile acids), and polymer carriers (e.g., polyesters and polyanhydrides); and a compound of the invention. In certain embodiments, the foregoing formulations render the compound of Formula I* bioavailable for oral administration.
[0277] Formulations of the present invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored base, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or suspension in a water-soluble or water-insoluble liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia), and / or as a mouthwash, etc., each containing a predetermined amount of a compound of formula I* as the active ingredient. The compound of formula I* may also be administered in the form of a bolus, electuary or paste.
[0278] In the solid dosage forms for oral administration of the present invention (capsules, tablets, pills, dragees, powders, granules, trouch, etc.), the active ingredient (salt or salt form, especially as described in Examples A to K above) is mixed with: one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and / or any of the following: (1) fillers or extenders, such as starch, lactose, sucrose, glucose, mannitol and / or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and / or gum arabic; (3) humectants, such as glycerol; (4) disintegrants, such as Agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates and sodium carbonate; (5) solution retardants such as paraffin; (6) absorption promoters such as quaternary ammonium compounds and surfactants such as poloxamers and sodium lauryl sulfate; (7) wetting agents such as, for example, cetyl alcohol, glyceryl monostearate and nonionic surfactants; (8) absorbents such as kaolin and bentonite; (9) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, zinc stearate, sodium stearate, stearic acid and mixtures thereof; (10) coloring agents; and (11) controlled release agents such as crospovidone or ethylcellulose. In the case of capsules, tablets and pills, the pharmaceutical composition may also contain a buffer. Similar types of solid compositions may also be used as fillers in soft and hard shell gelatin capsules using such excipients as lactose or milk sugar and high molecular weight polyethylene glycols.
[0279] Tablets can be prepared by compression or molding (optionally with one or more auxiliary ingredients). Compressed tablets can be prepared using a binder (e.g., gelatin or hydroxypropyl methylcellulose), a lubricant, an inert diluent, a preservative, a disintegrant (e.g., sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), a surfactant or a dispersant. Molded tablets can be prepared by molding a mixture of powdered compounds moistened with an inert liquid diluent in a suitable machine.
[0280] The terms "treatment" or "treating" are specifically intended to also cover prevention, therapy and cure.
[0281] Drug combinations
[0282] The present invention particularly relates to the use of compounds of formula I*, in particular compounds as defined in Examples A to K above, in the treatment of one or more diseases mentioned herein; wherein the response to the treatment is beneficial, as demonstrated, for example, by partial or complete removal of one or more symptoms of the disease up to complete cure or remission.
[0283] Compounds of formula (I*) may also be used in combination with any one or more of the following pharmaceutical compounds and treatments:
[0284] BCR-ABL inhibitor: Imatinib Inilotinib hydrochloride; Nilotinib Dasatinib (BMS-345825); Bosutinib (SKI-606); Ponatinib (AP24534); Bafetinib (INNO406); Danusertib (PHA-739358), AT9283 (CAS 1133385-83-7); Saracatinib (AZD0530); and N-[2-[(1S,4R)-6-[[4-(cyclobutylamino)-5-(trifluoromethyl)-2-pyrimidinyl]amino]-1,2,3,4-tetrahydronaphthalen-1,4-imin-9-yl]-2-oxoethyl]-acetamide (PF-03814735, CAS 942487-16-3).
[0285] ALK inhibitor: PF-2341066 ( Crizotinib); 5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrimidine-2,4-diamine; GSK1838705A, and CH5424802.
[0286] BRAF inhibitors: vemurafenib (PLX4032); LGX818 and dabrafenib.
[0287] FLT3 inhibitor - sunitinib malate (sunited with Pfizer under the trade name PKC412 (midostaurin); tandutinib, sorafenib, sunitinib, midostaurin, lestaurine, KW-2449, quizartinib (AC220), and crenolanib.
[0288] MEK inhibitor – trametinib.
[0289] Vascular endothelial growth factor (VEGF) receptor inhibitors: Bevacizumab (developed by Genentech / Roche under the trade name 1-[(4-pyridin-6-yl)-2-[(4-pyridin-2-yl)-1-[(4-pyridin-6-yl)-2-[(4-pyridin-6 ... 02 / 066470), pasireotide (also known as SOM230 and described in PCT Publication No. WO 02 / 010192), sorafenib (trade name for sale);
[0290] HER2 receptor inhibitors: Trastuzumab (manufactured by Genentech / Roche under the trademark ), neratinib (also known as HKI-272, (2E)-N-[4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide, and described in PCT Publication No. WO 05 / 028443), lapatinib or lapatinib ditosylate (marketed by GlaxoSmithKline under the trademark ), Trastuzumab emtansine (in the United States, ado-trastuzumab emtansine, trade name Kadcyla) - an antibody-drug conjugate consisting of the monoclonal antibody trastuzumab (Herceptin) linked to the cytotoxic agent maytansine (DM1);
[0291] CD20 antibody: Rituximab (developed by Genentech / Roche under the trademark and tositumomab (sold by GlaxoSmithKline under the trademark ofatumumab (sold by GlaxoSmithKline under the trademark for sale);
[0292] Tyrosine kinase inhibitors: Erlotinib hydrochloride (manufactured by Genentech / Roche under the trademark ), linifanib (N-[4-(3-amino-1H-indazole-4-yl)phenyl]-N'-(2-fluoro-5-methylphenyl)urea, also known as ABT 869, available from Genentech), sunitinib malate (sold by Pfizer under the trade name ), bosutinib (4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile, also known as SKI-606 and described in U.S. Pat. No. 6,780,996), dasatinib (sold by Bristol-Myers Squibb under the trade name ), armala (also known as pazopanib, marketed by GlaxoSmithKline under the trade name ), imatinib and imatinib mesylate (sold by Novartis under the trade name and for sale);
[0293] DNA synthesis inhibitors: Capecitabine (manufactured by Roche under the trademark Gemcitabine hydrochloride (sold by Eli Lilly and Company under the trademark Nelarabine ((2R,3S,4R,5R)-2-(2-amino-6-methoxy-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol), sold by GlaxoSmithKline under the trade name and for sale);
[0294] Antineoplastic drugs: Oxaliplatin (developed by Sanofi-Aventis under the trade name and described in U.S. Pat. No. 4,169,846);
[0295] Epidermal growth factor receptor (EGFR) inhibitors: gefitinib (trade name sold under the trade name 4-(dimethylamino)-2-butenamide, sold by Boehringer Ingelheim under the trade name 4-(dimethylamino)-2-butenamide, sold by Boehringer Ingelheim under the trade name 4-(dimethylamino)-2-butenamide, sold by Boehringer Ingelheim under the trade name 4-(dimethylamino)-2-butenamide, sold by Boehringer Ingelheim under the trade name 4-(dimethylamino)-2-butenamide, sold by Boehringer Ingelheim under the trade name Cetuximab (sold by Bristol-Myers Squibb under the trade name ), panitumumab (sold by Amgen under the trade name for sale);
[0296] HER dimerization inhibitor: Pertuzumab (developed by Genentech under the trademark for sale);
[0297] Human granulocyte colony-stimulating factor (G-CSF) regulator: Filgrastim (marketed by Amgen under the trade name for sale);
[0298] Immunomodulator: Afutol (available from Pegfilgrastim (available from Amgen under the trade name ), lenalidomide (also known as CC-5013, sold under the trade name ), thalidomide (sold under the trade name for sale);
[0299] CD40 inhibitor: Dacetuzumab (also known as SGN-40 or huS2C6, available from Seattle Genetics, Inc);
[0300] Pro-apoptotic receptor agonist (PARA): Duramin (also known as AMG-951, available from Amgen / Genentech);
[0301] Hedgehog antagonist: 2-chloro-N-[4-chloro-3-(2-pyridinyl)phenyl]-4-(methylsulfonyl)-benzamide (also known as GDC-0449 and described in PCT Publication No. WO 06 / 028958);
[0302] PI3K inhibitors: 4-[2-(1H-indazol-4-yl)-6-[[4-(methylsulfonyl)piperazin-1-yl]methyl]thieno[3,2-d]pyrimidin-4-yl]morpholine (also known as GDC 0941 and described in PCT Publication Nos. WO 09 / 036082 and WO 09 / 055730), 2-methyl-2-[4-[3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydroimidazo[4,5-c]quinolin-1-yl]phenyl]propionitrile (also known as BEZ 235 or NVP-BEZ 235 and described in PCT Publication No. WO 06 / 122806);
[0303] Phospholipase A2 inhibitors: Anagrelide (trade name for sale);
[0304] BCL-2 inhibitor: 4-[4-[[2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(4-morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]phenyl]sulfonyl]benzamide (also known as ABT-263 and described in PCT Publication No. WO 09 / 155386);
[0305] Mitogen-activated protein kinase (MEK) inhibitor: XL-518 (Cas No. 1029872-29-4, available from ACC Group);
[0306] Aromatase inhibitors: Exemestane (brand name: Letrozole (sold by Novartis under the trade name Anastrozole (sold under the trade name for sale);
[0307] Topoisomerase I inhibitors: irinotecan (trademarked by Pfizer Topotecan hydrochloride (sold by GlaxoSmithKline under the trade name for sale);
[0308] Topoisomerase II inhibitors: Etoposide (also known as VP-16 and etoposide phosphate, sold under the trade names and Teniposide (also known as VM-26, sold under the trade name for sale);
[0309] mTOR inhibitors: temsirolimus (marketed by Pfizer under the trade name sold under the name Defolimus (formally known as deferolimus, (1R,2R,4S)-4-[(2R)-2[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28Z,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxa-11,36-dioxa-4-azatricyclo[30.3.1.0 4,9 ]hexatriacont-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl dimethylphosphinate, also known as AP23573 and MK8669, and described in PCT Publication No. WO 03 / 064383), everolimus (marketed by Novartis under the trade name for sale);
[0310] Osteoclast bone resorption inhibitor: 1-Hydroxy-2-imidazol-1-yl-phosphorylethyl) phosphate monohydrate (sold by Novartis under the trade name for sale);
[0311] CD33 antibody-drug conjugate: Gemtuzumab ozogamicin (developed by Pfizer / Wyeth under the trade name for sale);
[0312] CD22 antibody-drug conjugate: inotuzumab (also known as CMC-544 and WAY-207294, available from Hangzhou Sage Chemical Co., Ltd.);
[0313] CD20 antibody-drug conjugate: Tetanisbetumomab (trade name for sale);
[0314] Somatostatin analogs: Octreotide (also known as octreotide acetate, under the trade name and Sandostatin for sale);
[0315] Synthetic interleukin-11 (IL-11): Oprelukin (developed by Pfizer / Wyeth under the trade name for sale);
[0316] Synthetic erythropoietin: Darbepoetin alfa (sold by Amgen under the trade name for sale);
[0317] Receptor activator of nuclear factor kappa B (RANK) inhibitor: Denosumab (marketed by Amgen under the trade name for sale);
[0318] Thrombopoietin mimetic peptide: Romiplostim (sold by Amgen under the trade name for sale);
[0319] Cell growth stimulator: Palifermin (sold by Amgen under the trade name for sale);
[0320] Anti-insulin-like growth factor-1 receptor (IGF-1R) antibodies: Figitumumab (also known as CP-751,871, available from ACC Group), robatumumab (CAS No. 934235-44-6);
[0321] Anti-CS1 antibody: elotuzumab (HuLuc63, CAS No. 915296-00-3);
[0322] CD52 antibody: Alemtuzumab (trade name for sale);
[0323] CTLA-4 inhibitors: Tremelimumab (IgG2 monoclonal antibody, available from Pfizer, formerly known as ticilimumab, CP-675,206), ipilimumab (CTLA-4 antibody, also known as MDX-010, CAS No. 477202-00-9);
[0324] PD1 inhibitors: nivolumab (also referred to herein as MDX-1106, MDX-1106-04, ONO-4538, BMS0936558, CAS Registry Number: 946414-94-4), disclosed, for example, in US 8,008,449 and having a sequence disclosed herein (or a sequence substantially identical or similar thereto, e.g., a sequence at least 85%, 90%, 95% identical or higher to a sequence specified in US 8,008,449); pembrolizumab (also referred to herein as pembrolizumab, MK-3475, MK03475, SCH-900475 or KEYTRUDA), disclosed, for example, in US 8,354,509 and WO 2009 / 114335, and having a sequence disclosed herein (or a sequence substantially identical or similar thereto, e.g., a sequence substantially identical or similar thereto, e.g., a sequence substantially identical or similar thereto, 2009 / 114335); immunoadhesins (e.g., immunoadhesins comprising an extracellular or PD-1 binding portion of PD-L1 or PD-L2 fused to a constant region (e.g., an Fc region of an immunoglobulin sequence); Pidilizumab (CT-011; Cure Tech) is a humanized IgG1k monoclonal antibody that binds to PD1 (Pidilizumab and other humanized anti-PD-1 monoclonal antibodies are disclosed in WO2009 / 101611); and AMP-224 (B7-DCIg; Amplimmune, disclosed in WO 2010 / 027827 and WO 2011 / 066342) is a PD-L2 that blocks the interaction between PD1 and B7-H1 Fc-fused soluble receptors; other PD-1 inhibitors, for example, anti-PD1 antibodies disclosed in US 8,609,089, US 2010028330 and / or US 20120114649.
[0325] PDL1 inhibitor: MSB0010718C (also known as A09-246-2; Merck Serono) is a monoclonal antibody that binds to PD-L1 and is disclosed, for example, in WO 2013 / 0179174 (and has a sequence substantially identical or similar thereto, e.g., to WO 2013 / 0179174). 2013 / 0179174);And an anti-PD-L1 binding antagonist selected from the following: YW243.55.S70, MPDL3280A (Genentech / Roche) (is a human Fc-optimized IgG1 monoclonal antibody that binds to PD-L1 (MDPL3280A and other human monoclonal antibodies to PD-L1 are disclosed in U.S. Patent No.: 7,943,743 and U.S. Publication No.: 20120039906); MEDI-4736, MSB-0010718C or MDX-1105 (MDX-1105, also known as BMS-936559, is an anti-PD-L1 antibody described in WO2007 / 005874; antibody YW243.55.S70 is an anti-PD-L1 antibody described in WO Anti-PD-L1) described in 2010 / 077634;.
[0326] LAG-3 inhibitors: BMS-986016 (also known as BMS986016; Bristol-Myers Squibb) is a monoclonal antibody that binds to LAG-3. BMS-986016 and other humanized anti-LAG-3 antibodies are disclosed in US 2011 / 0150892, WO 2010 / 019570, and WO 2014 / 008218.
[0327] GITR agonists; Exemplary GITR agonists include, for example, GITR fusion proteins and anti-GITR antibodies (e.g., bivalent anti-GITR antibodies), such as, for example, GITR fusion proteins as described in U.S. Pat. No. 6,111,090, European Patent No. 090505B1, U.S. Pat. No. 8,586,023, PCT Publication Nos. WO 2010 / 003118 and 2011 / 090754, or the anti-GITR antibodies, such as, for example, in U.S. Pat. No. 7,025,962, European Patent No. 1947183B1, U.S. Pat. No. 7,812,135, U.S. Pat. No. 8,388,967, U.S. Pat. No. 8,591,886, European Patent No. EP 1866339, PCT Publication No. WO 2011 / 028683, PCT Publication No. WO 2013 / 039954, PCT Publication No.: WO 2005 / 007190, PCT Publication No.: WO2007 / 133822, PCT Publication No.: WO 2005 / 055808, PCT Publication No.: WO 99 / 40196, PCT Publication No.: WO2001 / 03720, PCT Publication No.: WO99 / 20758, PCT Publication No.: WO2006 / 083289, PCT Publication No.: WO 2005 / 115451, U.S. Patent No.: 7,618,632, and PCT Publication No.: WO 2011 / 051726.
[0328] Histone deacetylase inhibitors (HDIs): Vorinostat (marketed by Merck under the trade name for sale below).
[0329] Anti-CTLA4 antibodies include tremelimumab (IgG2 monoclonal antibody, available from Pfizer, formerly known as ticilimumab, CP-675,206); and ipilimumab (CTLA-4 antibody, also known as MDX-010, CAS No. 477202-00-9).
[0330] Anti-TIM-3 antibody or antigen-binding fragment thereof.
[0331] Alkylating agents: Temozolomide (marketed by Schering-Plough / Merck under the trade name and Dactinomycin (also known as actinomycin-D and sold under the trade name ), melphalan (also known as L-PAM, phenylalanine mustard, and melphalan, sold under the trade names sold under the trade name), hexamethylmelamine (also known as hexamethylmelamine (HMM), Carmustine (sold under the trade name Bendamustine (sold under the trade name adenocarcinoma), busulfan (in the trade name and Carboplatin (sold under the trade name Lomustine (also known as CCNU, sold under the trade name Cisplatin (also known as CDDP, sold under the trade name and Sold under the trade name Cyclophosphamide (sold under the trade name and ), dacarbazine (also known as DTIC, DIC, and imidazole carboxamide, sold under the trade names Hexamethylmelamine (also known as hexamethylmelamine (HMM), sold under the trade name Ifosfamide (sold under the trade name Procarbazine (sold under the trade name ), dichloromethyldiethylamine (also known as nitrogen mustard or mustine) and nitrogen mustard hydrochloride, sold under the trade name Streptozotocin (sold under the trade name ), thiotepa (also known as thiophosphoramide, TESPA, and TSPA, sold under the trade names for sale);
[0332] Biological response modifier: Bacillus Calmette-Guerin (trade name and BCG), denileukin (sold under the trade name for sale);
[0333] Antitumor antibiotics: Doxorubicin (trade name and Bleomycin (sold under the trade name ), daunomycin (also known as dauorubicin hydrochloride, daunomycin, and rubidomycin hydrochloride, sold under the trade names daunomycin liposomes (daunomycin citrate liposomes, sold under the trade name ), mitoxantrone (also known as DHAD, sold under the trade name sold under the trade name Ellence TM Idabixin (sold under the trade name Idamycin Mitomycin C (sold under the trade name for sale);
[0334] Antimicrotubule agents: Estramustine (trade name for sale);
[0335] Cathepsin K inhibitor: Odancatib (also known as MK-0822, N-(1-cyanocyclopropyl)-4-fluoro-N 2 -{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)diphenyl-4-yl]ethyl}-L-leucinamide, available from Lanzhou Chon Chemicals (ACC Corp.) and ChemieTek, and described in PCT Publication No. WO 03 / 075836).
[0336] Epothilone B analogs: Ixabepilone (marketed by Bristol-Myers Squibb under the trade name for sale);
[0337] Heat shock protein (HSP) inhibitor: Tanespiramycin (17-allylamino-17-demethoxygeldanamycin, also known as KOS-953 and 17-AAG, available from SIGMA and described in U.S. Pat. No. 4,261,989);
[0338] TpoR agonist: Eltrombopag (developed by GlaxoSmithKline under the trade name and for sale);
[0339] Antimitotic agents: docetaxel (available from Sanofi-Aventis under the trade name for sale);
[0340] Adrenal steroid inhibitors: aminoglutethimide (trade name for sale);
[0341] Antiandrogen: Nilutamide (trade name and Bicalutamide (sold under the trade name Flutamide (sold under the trade name Fulexin TM for sale);
[0342] Androgens: Fluoxymesterone (trade name for sale);
[0343] Proteasome inhibitors: Bortezomib (trade name for sale);
[0344] CDK1 inhibitor: Alvocidib (also known as flavopiridol or HMR-1275, 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methyl-4-piperidinyl]-4-chromanone and described in U.S. Pat. No. 5,621,002);
[0345] Gonadotropin-releasing hormone (GnRH) receptor agonists: leuprolide or leuprolide acetate (marketed by Bayer AG under the trade name Sold by Sanofi-Aventis and by Abbott Labs in for sale);
[0346] Taxane antitumor agents: Cabazitaxel (1-hydroxy-7β,10β-dimethoxy-9-oxo-5β,20-epoxytax-11-ene-2α,4,13α-triyl-4-acetate-2-benzoate-13-[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropionate), larotaxel ((2α,3ξ,4α,5β,7α,10β,13α)-4,10-bis(acetoxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropionyl}oxy)-1-hydroxy-9-oxo-5,20-epoxy-7,19-cyclotax-11-ene-2-yl benzoate);
[0347] 5HT1a receptor agonist: Xaliproden (also known as SR57746, 1-[2-(2-naphthyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-1,2,3,6-tetrahydropyridine, and described in U.S. Pat. No. 5,266,573);
[0348] HPC vaccine: Developed by GlaxoSmithKline Sold by Merck sell;
[0349] Iron chelators: Deferasirox (available from Novartis under the trade name for sale);
[0350] Antimetabolite: Cladribine (2-chlorodeoxyadenosine, also known as ), 5-fluoropyrimidine (sold under the trade name ), 6-thioguanine (sold under the trade name Pemetrexed (sold under the trade name arabinoside (also known as cytosine arabinoside (Ara-C), sold under the trade name cytarabine liposomes (also known as liposome Ara-C, sold under the trade name DepoCyt TM Sold under the trade name ), hydroxyurea (sold under the trade name Droxia TM and Mylocel TM Fludarabine (sold under the trade name Sold under the trade name Cladribine (also known as 2-chlorodeoxyadenosine (2-CdA), sold under the trade name Leustatin TM ), methotrexate (also known as methotrexate, methotrexate sodium (MTX), and under the trade name and Trexall TM Sold under the trade name for sale);
[0351] Bisphosphonates: Pamidronate (trade name Zoledronic acid (sold under the trade name for sale);
[0352] Demethylating agent: 5-azacitidine (trade name Sold under the trade name for sale);
[0353] Plant alkaloids: Paclitaxel protein-bound (trade name ), vinblastine (also known as vinblastine sulfate, vinblastine, and VLB, sold under the trade names and sold under the trade names of and Vincasar Sold under the trade name ), paclitaxel (sold under the trade names Taxol and Onxal TM for sale);
[0354] Retinoids: alitretinoin (trade name Retinoic acid (all-trans retinoic acid, also known as ATRA, sold under the trade name isotretinoin (13-cis-retinoic acid, sold under the trade name and Bexarotene (sold under the trade name for sale);
[0355] Glucocorticoids: Hydrocortisone (also known as cortisone, hydrocortisone sodium succinate, hydrocortisone sodium phosphate, and under the trade names Hydrocortisone phosphate, Hydrocort and Dexamethasone ((8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthrene-3-one), Hydroprednisolone (sold under the trade name and Sold under the trade name Liquid and Methylhydroprednisolone (also known as 6-methylhydroprednisolone, methylhydroprednisolone acetate, methylhydroprednisolone sodium succinate, and sold under the trade name and for sale);
[0356] Cytokines: Interleukin-2 (also known as aldesleukin and IL-2, in the trade names ), interleukin-11 (also known as oprevelkin, sold under the trade name alpha interferon alfa (also known as IFN-α, sold under the trade name A and for sale);
[0357] Estrogen receptor downregulators: Fulvestrant (trade name and LSZ102;
[0358] Anti-estrogen: Tamoxifen (trade name for sale);
[0359] Toremifene (trade name for sale);
[0360] Selective estrogen receptor modulators (SERMs): Raloxifene (trade name for sale);
[0361] Luteinizing hormone-releasing hormone (LHRH) agonists: Goserelin (also known as for sale);
[0362] Progesterone: Megestrol acetate (also known as megestrol acetate, in the trade name for sale);
[0363] Other cytotoxic agents: Arsenic trioxide (available under the trade name Asparaginase, also known as L-asparaginase, Erwinia L-asparaginase, sold under the trade name and for sale);
[0364] The compounds of formula (I*) may also be used in combination with the following adjunctive therapies:
[0365] Antiemetic drugs: NK-1 receptor antagonist: casopitant (developed by GlaxoSmithKline under the trade name and sold below); and
[0366] Cytoprotectant: Amifostine (trade name sold under the trade name folinic acid), folinic acid (also known as calcium folinic acid, aurantium factor, and folinic acid).
[0367] Immune checkpoint inhibitors: In one embodiment, the combination therapy disclosed herein includes inhibitors of inhibitory molecules of immune checkpoint molecules. The term "immune checkpoint" refers to a group of molecules on the cell surface of CD4 and CD8 T cells. These molecules can be effectively used as "brakes" to downregulate or inhibit anti-tumor immune responses. Immune checkpoint molecules include but are not limited to programmed death 1 (PD-1), cytotoxic T lymphocyte antigen 4 (CTLA-4), B7H1, B7H4, OX-40, CD137, CD40 and LAG3 that directly inhibit immune cells, and immunotherapeutics that can be used as immune checkpoint inhibitors available in the method of the present invention include but are not limited to PD-L1, PD-L2, CTLA4, TIM3, LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 and / or TGFRβ inhibitors. The inhibition of inhibitory molecules can be performed by inhibition at the DNA, RNA or protein level. In an embodiment, inhibitory nucleic acids (e.g., dsRNA, siRNA or shRNA) can be used to inhibit the expression of inhibitory molecules. In other embodiments, the inhibitor of the inhibitory signal is a polypeptide, for example, a soluble ligand or an antibody or antigen-binding fragment thereof that binds to an inhibitory molecule.
[0368] In certain embodiments, the anti-PD-1 molecules having Formula I* described herein are administered in combination with one or more other PD-1, PD-L1 and / or PD-L2 inhibitors known in the art. The antagonist can be an antibody, an antigen-binding fragment thereof, an immunoadhesin, a fusion protein, or an oligopeptide.
[0369] Examples
[0370] The following examples (also specific inventive examples) are provided to illustrate the present invention without limiting the scope otherwise defined herein. Abbreviations used: Ac (acetyl or acetate); ACN (acetonitrile); Boc (tert-butyloxycarbonyl); Brine (saturated sodium chloride solution at room temperature); Bu (butyl); Dba (dibenzylideneacetone); DCM (dichloromethane); DIPEA (di(isopropyl)ethylamine); DMAc (N,N-dimethylacetamide); DMP (Dess-Martin reagent); DMSO (dimethyl sulfoxide); Dppf (diphenylphosphino); EA (ethyl acetate); ee (enantiomeric excess); Ent (enantiomer); eq or eq (equivalent); Equiv (equivalent) ); Et (ethyl); GC (gas chromatography); hr (s) (hours); HPLC (high performance liquid chromatography); IPA (isopropyl alcohol); IPAc (isopropyl acetate); IT (internal temperature (in the reaction mixture)); L (liter); LDA (lithium diisopropylamide); LiHMDS (lithium bis(trimethylsilyl)amide); LOQ (limit of quantification); Me (methyl); Me-THF (2-methyltetrahydrofuran); MTBE (methyl tert-butyl ether); NBS (N-bromosuccinimide); NMR (nuclear magnetic resonance); qnmr (quantitative NMR); i Pr or IP (isopropyl); PSC-1, 2, etc. (process steering control-1); Rt or RT (room temperature (about 20°C to 23°C)); sat (saturated (at RT)); TBS (tert-butyl-dimethylsilyl); TBSCl (tert-butyldimethylchlorosilane); THF (tetrahydrofuran); TLC (thin layer chromatography); TsCl (toluenesulfonyl chloride); V (volumetric); and Xantphos (4,5-bis(diphenylphosphino)-9,9-dimethylxanthene).
[0371] Experimental Procedure:
[0372] XRPD (X-ray powder diffraction) data were obtained using reflection mode as follows: Diffraction patterns were obtained on a Bruker D8 Advance system in reflection mode using a zero-background SI-sample holder. The samples were measured at room temperature without sample rotation. Data were obtained between 2° and 40°C 2θ with a step size of 0.017° and a step time of 0.3 s. Diffraction peak positions were calculated using the system evaluation software.
[0373] DSC (Differential Scanning Calorimetry) / TGA (Thermogravimetric Analysis) data were obtained as follows: Thermal analysis was performed using DSC or TGA. The DSC and TGA systems were TA-Instruments Discovery. For DSC, approximately 2-4 mg of sample was prepared in an aluminum crucible with a pinhole cover. Thermal behavior was determined between 30°C and 300°C using a heating rate of 10°C / min. The same heating rate and temperature range were applied to TGA, whereby approximately 5-15 mg of sample was filled into a sealed Al-crucible, which was automatically pierced by a robotic autosampler prior to measurement. The onset of melting and enthalpy as well as weight loss relative to temperature were determined using the system evaluation software.
[0374] DVS / Dynamic Vapor Sorption data were obtained as follows: Dynamic Vapor Sorption was performed using the SMS Advantage system. Approximately 10 mg of sample was subjected to varying humidities between 0% RH and 95% RH at 25°C. Evaluation was performed using the system software.
[0375] Example 1
[0376] Compounds having formula I ((3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazine- The synthesis method of 2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decane-4-amine):
[0377] The overall synthesis can be described by the following reaction scheme A:
[0378] Option A:
[0379]
[0380]
[0381] Step a
[0382]
[0383] To a solution of A1 (10.4 kg, 100 mol, 1.0 Eq) in CH2Cl2 (50 L) was added imidazole (8.16 kg, 120 mol, 1.2 eq) and TBSCl (18 kg, 120 mol, 1.2 Eq) at 0°C. After addition, the mixture was stirred at 0°C for 4 h. GC showed that the reaction was complete. (A1 / (A1+A2)<1%). The reaction mixture was quenched with saturated NaHCO3 (14 L) at 0°C-5°C. The phases were separated. The organic phase was washed with brine (14 L). The organic layer was dried over Na2SO4 and concentrated in vacuo at 40°C-45°C to give A2 (23.3 kg, content 88%, yield 94%), which was used directly in the next step. 1H NMR (400MHz, CDCl3) δ = 4.35 (d, J = 8.8Hz, 1H), 3.74 (s, 3H), 2.48 (s, J = 8.8Hz, 3H), 0.93 (s, 9H), 0.09 (s, 6H).
[0384] Step b
[0385]
[0386] To a solution of A2 (7.5 kg, 34.3 mol, 1.0 Eq) and N,O-dimethylhydroxylamine hydrochloride (6.69 kg, 68.6 mol, 2.0 Eq) in THF (20 L) was added (isopropyl) magnesium chloride (2M, 51.45 L, 3.5 Eq) dropwise at 0°C and N2 for 5-6 h. After addition, the reaction mixture was stirred at 0°C for 1 h, and GC showed that the reaction was complete (A2 / (A2+A3)<2%). The mixture was slowly quenched with NH4Cl (25 L) by keeping the temperature at 0°C-5°C. After addition, the reaction mixture was stirred for 30 min. The phases were separated. The aqueous layer was extracted with EA (2x 20 L). The combined organic phases were washed with brine (25 L), dried with Na2SO4, and concentrated to give A3 (9.4 kg, content 86%, yield 95%), which was used directly in the next step. 1 H NMR (400MHz, CDCl3) δ = 4.67 (m, J = 6.6Hz, 1H), 3.70 (s, 3H), 3.21 (s, 3H), 3.17 (d, 3H) 2.48 (s, J = 6.6Hz, 3H), 0.90 (s, 9H), 0.10 (s, 3H), 0.08 (s, 3H).
[0387] Step c
[0388]
[0389] To a solution of A3 (7.1 kg, 86% content, 24.65 mol, 1.0 Eq) in DCM (30 L) was added a solution of LiAlH4 (2.4 M, 11.3 L, 1.1 Eq) dropwise at -70 ° C and N2. The reaction mixture was then stirred at -70 ° C for 3 h, and TLC showed that the reaction was complete (PSC-1). The mixture was warmed to 0 ° C and then quenched with saturated potassium sodium tartrate (35 L) at 0 ° C. After the addition, DCM (20 L) was added and stirred at 20 ° C-25 ° C for 2 h. The phases were separated. The aqueous layer was extracted with DCM (25 L). Saturated citric acid (45 L) was added to the combined organic phases and stirred at 0 ° C for 8 h. The phases were separated. The organic phase was washed with NaHCO3 (25 L), brine (25 L), dried with Na2SO4, and the solvent was removed in vacuo at 25 ° C-30 ° C. n-Heptane (10 L) was added to the residue and concentrated in vacuo at 30-35° C. n-Heptane (10 L) was added to the residue again and concentrated in vacuo at 30-35° C. to give A4 (4.2 kg, content 60%, yield 54%), which was used directly in the next step.
[0390] Step d
[0391]
[0392] Under N2, 2.5M n-BuLi (12.12L, 30.3mol, 1.5eq) was added to a solution of diisopropylamine (3.06kg, 30.3mol, 1.5eq) in THF (20L) cooled to about -10°C. The resulting mixture was stirred at about -10°C for 30min, and then a solution of A5 (5.2kg, 20.20mol, 1.0eq) in THF (10L) was slowly added. After addition, the reaction mixture was stirred at -10°C for 30min and then cooled to -50°C. A4 (4.18kg, 22.22mol, 1.1eq) was added dropwise. After addition, the reaction mixture was stirred at -50°C for 30min. At -50°C, the mixture was quenched with saturated NH4Cl aqueous solution (30L) and water (10L). The reaction mixture was warmed to 20°C-25°C. Separate the phases. The aqueous phase was extracted with EA (3 x 20 L). All organic phases were combined and washed with brine (20 L), then concentrated to a yellow oil, which was purified by column (silica gel, 100-200 mesh, eluted with n-heptane:EA from 50:1 to 10:1) to give A6 (5.5 kg, 90% content, 55% yield) as a light yellow oil. 1H NMR(400MHz, CDCl3)δ=4.35-4.15(m,2H),3.95-3.74(m,3H),3.52(m,2H),2.67(m,2H),2.12 -1.98(m,2H),1.75-1.52(m,4H),1.49(s,9H),1.35-1.10(m,6H),0.98(s,9H),0.02(s,6H).
[0393] Step e
[0394]
[0395] To a solution of A6 (11.4 kg, 25.58 mol, 1.0 eq) in THF (60 L) was added LiBH4 (836 g, 38.37 mol, 1.5 eq) in portions at 5°C-10°C, and the reaction mixture was stirred at 20°C-25°C for 18 h. HPLC showed that the reaction was complete (A6 / (A6+A7)<2%). The mixture was cooled to 10°C and slowly quenched with saturated NaHCO3 solution (15 L) and water (25 L) under vigorous stirring. After gas formation ceased, vacuum filtration was applied to remove solids. The solids were washed with EA (2 x 15 L). The phases were separated; the aqueous phase was extracted with EA (3 x 15 L). All organic phases were combined, washed with brine (15 L), and concentrated to give crude A7 (13.8 kg, content 58%, yield 77%), which was used directly in the next step.
[0396] Step f
[0397]
[0398] To a solution of A7 (8 kg, 19.82 mol, 1.0 eq) in THF (40 L) was added TsCl (5.28 kg, 27.75 mol, 1.4 eq) at 10-15 °C under nitrogen atmosphere. After addition, the mixture was cooled to 0 °C, and 1 M LiHMDS (29.7 L, 29.73 mol, 1.5 eq) was added dropwise over 2 h. After addition, the mixture was stirred at 0 °C for 3 h. HPLC showed that the reaction was complete (PSC-1A7 / (A7+A8)<7%). TBAF (20.72 kg, 65.67 mol, 3.3 eq) was added to the mixture at 0 °C, and the reaction mixture was stirred at 25-30 °C for 48 h. HPLC showed that the reaction was complete (PSC-2, A9-intermediate / (A9-intermediate+A9)<2%). The mixture was quenched with saturated aqueous sodium bicarbonate solution (32 L) and stirred at 0 ° C for 30 min. The phases were separated and the aqueous phase was extracted with EA (3 x 20 L). The combined organic phases were washed with brine (20 L), dried over Na2SO4, and concentrated into a yellow oil, which was purified by column (eluted with n-heptane:EA from 10:1 to 1:1) to obtain A9 (4.42 kg, 90% content, 74% yield) as a light yellow solid.
[0399] Step g
[0400]
[0401] DMP (9.36 kg, 23.58 mol, 1.6 eq) was added in batches to a solution of A9 (4.0 kg, 14.74 mol, 1.0 eq) in DCM (40 L) cooled on an ice bath to give a suspension. After addition, the mixture was stirred at 20°C-25°C for 4 hours. HPLC showed that the reaction was complete (A9 / (A9+A10)<2%). DCM (30 L) was added at 0°C. After addition, the mixture was quenched with saturated Na2SO3 aqueous solution (20 L). The mixture was stirred at 0°C for 30 min, filtered, and the white solid was washed with DCM (2 x 15 L). The phases were separated, and the organic phase was cooled to 0°C, to which saturated NaHCO3 aqueous solution (20 L) was added and stirred for 1 h. The phases were separated and the organic phase was washed with brine (25 L), dried over Na2SO4, and concentrated to a yellow oil, which was purified by column (eluting with n-heptane:EA from 50:1 to 10:1) to give A10 (3.70 kg, 88% content, 95.3% ee, 82% yield) as a white solid. 1HNMR (400MHz, DMSO-d6) δ = 4.20 (d, J = 8.0Hz, 1H), 3.98-3.67 (m, 4H), 3.08-2.90 (m, 2H), 1.54-1.39 (m, 13H), 1.18 (d, J = 8.0Hz, 3H).
[0402] Step h
[0403]
[0404] To a solution of A10 (4.60 kg, 17.08 mol, 1.0 eq) in THF (40 L) at 25 °C, Ti(OEt)4 (15.58 kg, 68.32 mol, 4.0 eq) and (R)-tert-butylsulfenamide (4.14 kg, 34.16 mol, 2.0 eq) were added. After addition, the mixture was heated to 70 °C and stirred for 20 h. HPLC showed that the reaction was complete (PSC-1, A10 / (A10+A12)<4%). The mixture was cooled to -30°C to -40°C, and MeOH (4 L) was added dropwise over 30 minutes and stirred for 1 h. A 2M LiBH4 (8.1 L) solution was added dropwise to the reaction mixture at -40°C to -50°C and stirred for 1 h. HPLC showed that all the imine was consumed (PSC-2, A12 / (A12+A13)<1%). The mixture was warmed to -30 ° C and stirred for 1 h, then warmed to 0 ° C and stirred for 1 h within 2 hours, then warmed to 20 ° C-25 ° C and stirred for 30 min. IPAC (25 L) was added to the above mixture, and NaHCO (5 L) was added dropwise at 25 ° C in about 1 h and stirred for 30 min. The mixture was vacuum filtered and the cake was washed with IPAC (8x15 L). The combined organic phase was washed with brine (25 L) and then evaporated under vacuum to obtain A13 solution (about 28 kg), which was used in the next step.
[0405] Step i
[0406]
[0407] At -5 ° C, 4M HCl / IPA (8.54 L, 34.16 mol, 2.0 eq) was added dropwise to a mixture of A13 in IPAC (about 28 kg, 17.08 mol, 1.0 eq) and stirred at -5 ° C for 5 h. HPLC showed that A13 was completely consumed (A13 / (A14+A13)<1%). MTBE (25 L) was added to the above mixture within 30 minutes and stirred at -5 ° C for 30 min. The solid was collected by vacuum filtration. The cake was washed with MTBE (2 x 2.5 L). The wet cake was used directly in the next step.
[0408] Step j
[0409]
[0410] Wet solid A14 (from 9.2kg of A10) is stirred in MTBE (76L) at 25°C, then 16% NaOH (9.84kg) solution is added dropwise to the MTBE suspension while keeping IT < 10°C. After addition, the mixture is stirred for 15min, and all solids are dissolved at 0°C. The organic phase is separated and the aqueous phase is extracted with MTBE (2x 20L). The combined organic phases are washed with brine (10L) and evaporated under vacuum to remove all MTBE. ACN (24L) is added to the above-mentioned residue, and the mixture is evaporated under vacuum to remove the organic solvent and obtain crude A15 (5.42kg, qnmr 90%, 18.04mol, 1.0eq). ACN (34.68kg) is added to the above-mentioned residue and stirred for 10min at 65°C. To the mixture was added a solution of (-)-O-acetyl-D-mandelic acid (3.15 kg, 16.2 mol, 0.9 eq) in ACN (11.6 kg) dropwise over 3 h (1 / 3 was added first, stirred for 0.5 h, then the remainder was added). The mixture was stirred at 65 ° C for 1 h, then cooled to 25 ° C over 4 hours and stirred at 25 ° C for 12 h. The solid was collected by vacuum filtration, and the cake was washed with pre-cooled ACN (2 x 15 kg) (PSC-1) and dried under vacuum to give A16 (7.36 kg, 46% from A10 to A16). 1 H NMR (400MHz, DMSO-d6)δ=7.43-7.29(m,5H),5.58(s,2H),4.12-4.07(m,1H),3.75-3.65(m,3H),3.51-3.4 9(m,1H),3.18-3.17(m,1H),2.84(bs,2H),2.05(s,3H),1.60-1.40(m,13H),1.14-1.12(d,J=8.0Hz,3H).
[0411] Step k
[0412]
[0413] To a solution of A16 (15 g) in MeOH (90 mL) was added 5N HCl / IPA (45 mL) at room temperature over 15 minutes. After addition, the mixture was stirred for 6 hours. IPAC (180 mL) was added dropwise to the above mixture at room temperature over 1 h. The resulting mixture was stirred for another 30 minutes and then cooled to 0°C-5°C. The mixture was stirred at 0°C-5°C for another 2 hours and the precipitate was collected by filtration. The cake was washed with IPAC (45*2 mL) and dried overnight in vacuo at 60°C to give the product as a white solid. 1 H NMR (400MHz, DMSO-d6) δ = 9.37 (br s, 1H), 9.25 (br s, 1H), 8.42 (br s,3H),4.26-4.17(m,1H),3.72(ABq,J=9.1Hz,2H),3.50-3.41(m,1H),3.28-3.18(m, 1H),3.18-3.09(m,1H),2.99-2.74(m,2H),2.07-1.63(m,4H),1.22(d,J=6.5Hz,3H).
[0414] Step 1
[0415]
[0416] To a mixture of A17 (10 g) and Z17a (9.5 g) in DMAC (60 mL) was added K2CO3 (22.5 g) and H2O (40 mL) at room temperature. The mixture was degassed with nitrogen and stirred at 90°C overnight. The mixture was cooled to room temperature and diluted with Me-THF (500 mL) and H2O (280 mL). The organic phase was separated and the aqueous phase was extracted with Me-THF (300 mL*2). The combined organic phases were washed with brine (200 mL*3) and concentrated under vacuum to remove most of the solvent. The residue was diluted with IPA (60 mL) and H2O (20 mL), stirred at 50°C for 1 h, cooled to 5°C within 3 h, and stirred at this temperature for 1 h. The solid was collected by vacuum filtration and dried under vacuum to give the product (12 g, 87.4%) as a yellow solid. 1H NMR (400MHz, DMSO-d6) δ = 7.64 (d, J = 6.2Hz, 1H), 7.62 (s, 1H), 6.26 (s, 2H), 6. 13(s,2H),5.74(d,J=5.3Hz,1H),4.12-4.02(m,1H),3.90-3.78(m,2H),3.67( d,J=8.4Hz,1H),3.49(d,J=8.4Hz,1H),3.33(s,2H),2.91(d,J=5.1Hz,1H),1. 78-1.68(m,1H),1.67-1.57(m,1H),1.56-1.41(m,2H),1.08(d,J=6.5Hz,3H).
[0417] Example 2
[0418] Formation of the succinate salt of the compound having formula I:
[0419] The reaction is summarized by the following reaction scheme:
[0420]
[0421] To a mixture of A18 (10 g) in MeOH (76 g) and H2O (24 g) was added succinic acid (2.94 g) at room temperature. The mixture was heated to 50 ° C and stirred for 30 minutes to dissolve all solids. The solution was added to IPA (190 mL) at 60 ° C-65 ° C. The resulting mixture was stirred at 60 ° C for > 5 hours, cooled to -15 ° C within 5 hours and stirred at this temperature for > 4 hours. The solid was collected by vacuum filtration and dried under vacuum to obtain the product (10.8 g, 82.8%) as an off-white solid. 1 H NMR (400MHz, DMSO-d6) δ = 7.64 (d, J = 6.2Hz, 1H), 7.63 (s, 1H), 6.26 (s, 2H), 6.16 (s, 2H), 5.74 (d, J = 5.3Hz, 1H), 4.12-4.02 (m, 1H), 3.90-3.78 (m ,2H),3.67(d,J=8.4Hz,1H),3.49(d,J=8.4Hz,1H),3.33(s,2H),2.91(d,J=5.1Hz,1H),2.34(s,4H),1.71-1.60(m,4H),1.13(d,J=6.5Hz,3H).
[0422] In a particular variation, the reaction follows the following reaction scheme which also includes optional grinding to produce the final product:
[0423]
[0424] Example 3
[0425] Formation of Intermediate Z17a (3-((2-amino-3-chloropyridin-4-yl)thio)-6-chloropyrazin-2-amine) Variant 1:
[0426] Compound Z17a is obtained by reaction according to the following reaction scheme:
[0427]
[0428] In detail, the synthesis of compound Z17a was carried out as follows:
[0429] Step a
[0430]
[0431] Under nitrogen atmosphere, n-BuLi (2.5M, 7.6L) was added dropwise to a solution of 3-chloro-2-fluoropyridine (2kg) in THF (15L) at -78°C. The resulting mixture was then stirred for 1h. A solution of I2 (4.82kg) in THF (6L) was then added dropwise. After addition, the reaction mixture was stirred for 30 minutes, and then quenched with saturated Na2SO3 (10L) and heated to 20-25°C. Separate each phase. The aqueous phase was extracted with EA (2x 10L). The combined organic phases were washed with saturated Na2SO3 (2x 8L), brine (8L), and dried over Na2SO4. The organic phase was concentrated in vacuo. The residue was slurried in MeOH (4L), filtered and dried to obtain 3-chloro-2-fluoro-4-iodopyridine 1c (2.2kg, 68% yield).
[0432] Step b
[0433]
[0434] At 80°C, NH3 (gas) was passed into a solution of compound 1c (8 kg) in DMSO (48 L) overnight. TLC showed that the reaction was complete. The reaction mixture was cooled to RT. The reaction mixture was added to water (140 L). The solid was collected and washed with water (25 L) and dried to give Z17b (6.91 kg, 87% yield). 1 H NMR (400MHz, CDCl3) δ = 7.61 (d, J = 6.8Hz, 1H), 7.14 (s, J = 6.8Hz, 1H), 5.09 (bs, 2H).
[0435] Step c
[0436]
[0437] A solution of 2-amino-6-chloro-pyrazine 1a (1 kg, 7.69 mol) in DCM (15 L) was heated to reflux, to which NBS (417 g) was added in portions over 1 h. The reaction was cooled to room temperature. The reaction mixture was washed with water (3 L) and brine (3 L). The organic phase was evaporated and the residue was purified by column chromatography to give the product Z17f (3-bromo-6-chloropyrazine-2-amine) (180 g, 11% yield).
[0438] Step d
[0439]
[0440] At room temperature and nitrogen, to a solution of 3-bromo-6-chloropyrazine-2-amine Z17f (6.0 kg, 28.78 mol) in 1,4-dioxane (40 L) was added Pd(OAc)2 (64.56 g, 287.6 mmol), Xantphos (333 g, 575.6 mmol) and DIPEA (7.44 kg, 57.56 mol). After purging with nitrogen for another 30 minutes, methyl 3-mercaptopropionate (3.81 kg, 31.70 mol) was added to darken the orange mixture. The mixture was heated to 90 ° C. HPLC showed that the starting material was completely converted. The mixture was cooled to about room temperature and then diluted with EtOAc (40 L). After aging for 30 min under stirring, the entire mixture was filtered and the solid was washed with EtOAc (3x 15 L). The combined orange filtrate was concentrated to dryness, and the solid residue was suspended in DCM (45 L). The mixture was heated to 35-40 ° C and stirred for 1 h until all solids dissolved. Then n-heptane (45 L) was added dropwise. After completion of the addition, the mixture was cooled to 15 ° C -20 ° C and stirred for 1 h. The solids were collected by vacuum filtration and washed with cold 1: 1 DCM / heptane (25 L), then heptane (25 L) (PSC-2). The solids were dried over the weekend to give Z17d (5.32 kg, 75% yield). 1 H NMR (400MHz, CDCl3) δ = 7.83 (s, 1H), 4.88 (bs, 2H), 3.73 (s, 3H), 3.47 (t, J = 9.2Hz, 2H), 2.79 (t, J = 9.2Hz, 2H).
[0441] Step e
[0442]
[0443] To a solution of Z17d (8.0 kg, assay 95%, 30.68 mol) in THF (70 L) was added EtONa (prepared from 776 g Na and 13.6 L EtOH) at room temperature, and the mixture was stirred at ambient temperature for 1 hour. The mixture was then concentrated to a wet yellow solid by rotary evaporation, and the residue was suspended in DCM (40 L). The mixture was stirred under N2 for 16 h. The solid was collected by vacuum filtration, and the filter cake was washed with DCM (about 15 L) until the filtrate was colorless (PSC-2). The solid was then dried in vacuo to give Z17c (6.93 kg, qNMR 72%, 88% yield). 1 H NMR (400MHz, D2O) δ = 7.37 (s, 1H).
[0444] Step f
[0445]
[0446] Xantphos (233 g, 411 mmol, 0.015 eq), Pd2(dba)3 (186 g, 206 mmol, 0.0075 eq), Z17b (7.13 kg, 28.02 mol) and DIPEA (7.02 kg, 54.46 mol) were added to a mixture of Z17c (6.95 kg, 72% assay, 27.23 mol) in 1,4-dioxane (72 L). The system was evacuated and purged with nitrogen three times. The mixture was stirred at 65 ° C for 16 h under N2. The mixture was cooled to room temperature and water (50 L) was added and filtered. The cake was washed with EA (25 L). The filtrate was extracted with EA (4 x 20 L). The organic phase was concentrated in vacuo to give a crude product, which was combined with the filter cake. DCM (60 L) was then added to the crude product and stirred at 25 ° C-30 ° C for 18 h, and then filtered. The filter cake was slurried with CH2Cl2 (30 L) for 4 hrs and filtered. The filter cake was slurried in CH2Cl2 (30 L) for 16 hrs and filtered. The filter cake was then dried in vacuo to afford Z17a (3-((2-amino-3-chloropyridin-4-yl)thio)-6-chloropyrazin-2-amine; 9.1 kg, 84%) as a light yellow solid. 1 H NMR (400MHz, DMSO-d6) δ = 7.89 (s, 1H), 7.7 (d, J = 7.6Hz, 1H), 7.18 (bs, 2H), 6.40 (bs, 2H), 5.97 (d, J = 7.6Hz, 1H).
[0447] Example 4
[0448] Alternative formation of intermediate Z17a (also referred to herein as Y7a):
[0449] By alternative approach and according to the preferred reaction method, the compound having the formula Z17a is obtained according to the following reaction scheme:
[0450]
[0451] In detail, the synthesis of compounds having the formula Y7a=Z17a is carried out as follows:
[0452] Step a
[0453]
[0454] 2,3,5-Trichloropyrazine (70.50 g, 384.36 mmol, 1 equiv) and ammonia solution (25% wt, 364.00 g, 400 mL, 2.68 mol, 6.14 equiv) were added to a 1 L sealed reactor. The mixture was heated to 80 ° C and stirred for 24 h, and the reaction was completed. The reaction mixture was cooled to 30 ° C and filtered to obtain a brown filter cake. The brown filter cake was dissolved in acetone (50 mL) and filtered. Petroleum ether (300 mL) was added to the filtrate. The suspension was stirred for 4 h and filtered to obtain a crude product. The crude product was slurried in a mixed solvent of petroleum ether and acetone (10 / 1, 200 mL) and filtered to obtain the product Y7d (51.00 g, 307.91 mmol, 80% yield) as a light yellow solid. 1H NMR (400 MHz, DMSO-d6) δ = 7.63 (s, 1H).
[0455] Step b
[0456]
[0457] Na2S (10.816 g, 44 wt%, containing water of crystallization, 60.978 mmol) and toluene (100 mL) were added to a 200 mL round-bottom flask. The mixture was heated to reflux and water was removed using a Dean-Stark water separator (about 5-6 mL of water was distilled off). After cooling, the mixture was concentrated to dryness.
[0458] Y7d (5.000 g, 30.489 mmol) and 2-methylbutan-2-ol (50 mL) were added to the above-mentioned round-bottom flask, the reaction was heated to reflux and stirred for 36 h. After being cooled to 25 ° C, the mixture was filtered. The solvent of the filtrate was exchanged with n-heptane (5 V, 3 times, based on Y7d), and finally concentrated to 1 V of residue. THF (25 mL) was added to the residue and stirred at 25 ° C. The suspension was filtered and washed with THF / n-heptane (5 mL / 5 mL) to obtain a brown solid (6.200 g).
[0459] To another 200 mL round-bottom flask, the above brown solid (6.200 g), 10% brine (25 mL), Me-THF (30 mL) and n-Bu4NBr (9.829 g, 30.489 mmol) were added. The mixture was stirred at room temperature for 0.5 h, and the phases were separated. The organic phase was washed with 20% brine (25 mL), and the solvent was exchanged with isopropanol (5V*3 times, based on Y7d) to obtain an isopropanol solution of Y7c (27.000 g, HPLC area purity of 99.2%, 58.08% assay yield). 1H NMR (400 MHz, DMSO-d6) δ = 6.88 (s, 1H), 2.97–2.92 (m, 14H), 1.38–1.31 (m, 14H), 1.13-1.04 (m, 14H), 0.73–0.69 (t, 21H).
[0460] Step c
[0461]
[0462] A 25 mL round bottom flask was charged with Y7c (4.7 g, 23.27 wt %, IPA solution from step b, 2.723 mmol, 1.0 equiv), Y7b (1.052 g, 4.085 mmol, 1.5 equiv), 1,10-phenanthroline (0.05 g, 0.272 mmol) and water (8 mL). The mixture was purged with nitrogen three times and CuI (0.026 g, 0.136 mmol) was added under nitrogen atmosphere. The mixture was heated to 65 °C and stirred for 3 h and the reaction was completed. The reaction was cooled to room temperature and filtered, and the filter cake was washed with water (4 mL*3). The filter cake was slurried in MTBE (6 mL) for 30 min and filtered. The filter cake was washed with MTBE (6 mL) and dried to give Y7a, which is Z17a (565 mg, 72% yield).
[0463] Z17b was synthesized as described in Example 3, steps a and b.
[0464] Example 5
[0465] Alternative synthesis of intermediate Z17a:
[0466] According to another preferred method, the compound having formula Z17a is obtained according to the following reaction scheme:
[0467]
[0468] In detail, the reaction proceeds as follows:
[0469] Step a
[0470] Y7d was synthesized as described in Example 4, step a.
[0471] Step b
[0472]
[0473] Y7d (200 mg, 1.22 mmol, 1 equiv), dioxane (4 mL) were added to a three-necked round flask. The solution was evacuated and purged with nitrogen three times. Xantphos (14 mg, 0.024 mmol, 0.02 equiv), PdCl2(dppf) (8.9 mg, 0.012 mmol, 0.1 equiv) and DIPEA (0.32 g, 2.44 mmol, 2.0 equiv) were added under a nitrogen atmosphere. The solution was heated to 85°C overnight. The reaction was cooled and evaporated. The residue was purified by column chromatography (eluent / ethyl acetate / heptane=1 / 1) to give Z17d (259 mg, 0.99 mmol, 81%). 1 H NMR (400MHz, CDCl3) δ = 7.83 (s, 1H), 4.88 (bs, 2H), 3.73 (s, 3H), 3.47 (t, J = 9.2Hz, 2H), 2.79 (t, J = 9.2Hz, 2H).
[0474] The remaining steps were carried out as described in Example 4, steps e and f to afford Z17a. Z17b was synthesized as described in Example 3, steps a and b.
[0475] Example 6
[0476] (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2- Oxa-8-azaspiro[4.5]decane-4-amine succinate (1:1) hemihydrate variant H A ; Variant a)
[0477] 50 ml of ethanol and 2.5 ml of water are added to a 100 ml flask containing 3.0 g of (3S, 4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decane-4-amine free base (e.g. obtained as A18 as described in Example 1) and 848.0 mg of succinic acid. The mixture is heated to 50° C. to produce a clear solution. The temperature is reduced to 15° C. over a period of 3 hours. The solution is maintained at 15° C. and stirred overnight. The precipitated solid is separated by suction filtration, and 50 ml of acetone is added to produce a suspension. The suspension is stirred at 50° C. for 3 hours. The solid is separated by suction filtration and dried under vacuum at room temperature for 3 hours. The yield is about 60%.
[0478] The succinate salt appears as a highly crystalline solid with a melting point onset of 94.4°C and an associated enthalpy of 96 J / g. The succinate salt crystals appear as aggregates of broken clusters of plate-like particles.
[0479] Variant b)
[0480] 14.34 g of (3S, 4S) -8- (6-amino-5- ((2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) -3-methyl-2-oxa-8-azaspiro [4.5] decane-4-amine free form (e.g. obtained as A18 as described in Example 1) and 4.053 g of succinic acid were equilibrated in 100 mL of 95% EtOH at 50 ° C. 5 mL of water was added to the system and heated to 70-75 ° C. 95 mL of pure EtOH was added and heated for another 30 min. Stirred overnight at 25 ° C. The mixture was filtered, washed with EtOH, and dried in an oven under vacuum at room temperature. The yield was 87.5%.
[0481] The title succinate (1:1) hydrate salt variant H obtained according to any one of variants a) and b) A It is highly crystalline. It maintains a constant water content at room temperature between 10% RH and 50% RH. The succinate variant HA shows high solubility in aqueous media, indicating potential good bioavailability.
[0482] The following XRPD data (table of 2-theta values) were obtained (two variations):
[0483]
[0484] 1 H NMR(400MHz,DMSO-d6)δ6.16(s,2H),7.63(d,J=5.8Hz,2H),6.27(s,2H),5 .86–5.60(m,1H),4.25–4.05(m,1H),4.05–3.82(m,2H),3.75(d,J=8.7Hz, 1H),3.56(d,J=8.7Hz,1H),3.24(dddd,J=23.7,13.4,9.9,3.3Hz,2H),3.0 9(d,J=5.0Hz,1H),2.34(s,4H),1.77–1.38(m,4H),1.13(d,J=6.4Hz,3H).
[0485]
[0486]
[0487] Figure 1The obtained XRPD pattern is shown. Molar stoichiometry by NMR: 1:1.08 (base:succinic acid). At 50°C / 75%RH, the succinate salt showed acceptable levels of degradation in all four experimental excipient mixtures.
[0488] Example 7
[0489] (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2- Oxa-8-azaspiro[4.5]decane-4-amine hydrochloride
[0490] 50 mg of (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decane-4-amine free form and 23.35 mg of hydrochloric acid were equilibrated in 1 mL of ACN at 50° C. for 4 hours. Cooled to room temperature overnight and the mixture was filtered. This gave the hydrochloride salt.
[0491] The data indicated that a solvate may be formed. The following XRPD data (2-θ value table) were obtained:
[0492]
[0493] 1 H NMR (500MHz, DMSO-d6) δ7.70-7.57(m,2H),6.26(s,2H),6.17(s,2H),5.74(d,J=5.4Hz,1H),4.35(t,J=5.0Hz,1H),4.28-4.13(m,2H),4. 11(d,J=13.8Hz,1H),3.90(d,J=9.0Hz,1H),3.67(d,J=8.9Hz,1H),3.43(td,J=7.0,4.9Hz,1H),1.84-1.48(m,4H),1.23(d,J=6.6Hz,3H).
[0494]
[0495] Figure 2 The obtained XRPD pattern is shown.
[0496] Example 8
[0497] (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2- Oxa-8-azaspiro[4.5]decane-4-amine methanesulfonate
[0498] 50 mg of 3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decane-4-amine free form and 11.62 mg of methanesulfonic acid were equilibrated in 1 mL of THF at 50° C. Cool to room temperature overnight and filter the mixture. This gave the mesylate salt.
[0499] The data showed that solvate formation was possible. The following XRPD data were obtained (2-θ value table):
[0500]
[0501] 1 H NMR (500MHz, DMSO-d6) δ7.88 (s, 3H), 7.74-7.61 (m, 2H), 6.31 (s, 2H), 5.96 (d, J = 6.4Hz, 1H), 4.34-4.06 ( m, 4H), 3.88 (d, J = 9.0Hz, 2H), 3.47-3.31 (m, 3H), 2.31 (s, 6H), 1.85-1.40 (m, 4H), 1.22 (d, J = 6.5Hz, 3H).
[0502]
[0503] Figure 3 The obtained XRPD pattern is shown.
[0504] Example 9
[0505] (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2- Oxa-8-azaspiro[4.5]decane-4-amine fumarate
[0506] 50 mg of (3S, 4S) -8- (6-amino-5- ((2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) -3-methyl-2-oxa-8-azaspiro [4.5] decan-4-amine free form and 13.89 mg of fumaric acid were equilibrated in 1 mL of EtOH at 50 ° C. Cool to room temperature overnight and filter the mixture. This gives the fumarate salt.
[0507] The following XRPD data (2-θ value table) were obtained:
[0508]
[0509]
[0510] 1H NMR (500MHz, DMSO-d6) δ7.63(d,J=6.4Hz,2H),6.52(s,2H),6.26(s,2H),6.14(s,2H),5.74(d,J=5.3Hz,1H),4.20-4.02(m,1H),3.97(dd,J=19. 6,14.4Hz,2H),3.76(d,J=8.6Hz,1H),3.56(d,J=8.7Hz,1H),3.32-3.16 (m, 3H), 3.11 (d, J = 5.1Hz, 1H), 1.82-1.37 (m, 4H), 1.14 (d, J = 6.5Hz, 3H).
[0511]
[0512] Figure 4 The obtained XRPD pattern is shown.
[0513] Example 10
[0514] (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2- Oxa-8-azaspiro[4.5]decane-4-amine adipate (1:1) variant A
[0515] 30 ml of acetonitrile were added to a 100 ml flask containing 3.0 g of (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine and 1.0 mg of adipic acid. The resulting suspension was heated to 50° C. for 3 hours and then cooled to 15° C. over a period of 3 hours. The suspension was kept at 15° C. with stirring overnight. The solid was isolated by suction filtration and dried under vacuum at 40° C. for 12 hours. The yield of the resulting adipate modification A was about 80%.
[0516] The adipate salt appears as a highly crystalline solid with a melting point onset of 145.3°C and an associated enthalpy of 90 J / g. The adipate salt crystals appear as aggregates of plate-like particles.
[0517] Molar stoichiometry of NMR: 1:1.02 (base:adipic acid). The following XRPD data were obtained (2-theta value table):
[0518]
[0519] 1H NMR(400MHz, DMSO-d6)δ7.63(d,J=5.3Hz,2H),6.27(s,3H),6.14(s,2H),5.74(d, J=5.3Hz,1H),4.19–4.00(m,1H),3.98–3.77(m,2H),3.68(d,J=8.5Hz,1H),3.49( d,J=8.5Hz,1H),3.33(dddd,J=31.4,13.1,9.3,3.4Hz,2H),2.93(d,J=5.1Hz,1H) ,2.28–2.09(m,4H),1.80–1.56(m,2H),1.57–1.37(m,6H),1.09(d,J=6.4Hz,3H).
[0520]
[0521]
[0522] Figure 5 The obtained XRPD pattern is shown. When a mixture of drug ingredients containing mannitol, Ac-di-Sol and microcrystalline cellulose was used, the adipate salt showed strong degradation.
[0523] Example 11
[0524] (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2- Oxa-8-azaspiro[4.5]decane-4-amine succinate (1:1) anhydrous form variant A
[0525] 2.0 g of (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decane-4-amine free form and 1.13 g of succinic acid were added to an EasyMax reactor followed by 40 mL of ethanol. The resulting mixture was stirred at 25° C. for 3 days. The mixture was filtered. The solid phase was washed with 40 mL of ethanol and dried at ambient temperature. This gave the monosuccinate anhydrous form modification A.
[0526] The following XRPD data (2-θ value table) were obtained:
[0527]
[0528] 1H NMR(400MHz,DMSO-d6)δ7.73–7.53(m,2H),6.27(s,2H),6.16(s,2H),5.73 (d,J=5.4Hz,1H),4.26–4.03(m,1H),4.04–3.87(m,2H),3.75(d,J=8.7Hz, 1H),3.56(d,J=8.7Hz,1H),3.23(dddd,J=23.6,13.3,9.9,3.3Hz,2H),3.1 0(d,J=5.0Hz,1H),2.35(s,5H),1.72–1.40(m,4H),1.13(d,J=6.4Hz,3H).
[0529]
[0530] Figure 6 The obtained XRPD pattern is shown.
[0531] Example 12
[0532] (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2- Oxa-8-azaspiro[4.5]decane-4-amine succinate (2:1) hydrate variant H A
[0533] 2 g of (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decane-4-amine monosuccinate hydrate was converted to H A Add to a suitable flask. 20 mL of a mixture of acetonitrile / water (80:20, v / v) was added to the flask and the resulting suspension was stirred overnight. The mixture was filtered and dried to a solid phase at ambient temperature. This gave the hemisuccinate hydrate modification H A .
[0534] The following XRPD data (2-θ value table) were obtained:
[0535]
[0536]
[0537] 1H NMR (400MHz, DMSO-d6) δ7.73-7.50(m,2H),6.26(s,2H),6.14(s,2H),5.74(d,J=5.4Hz,1H),4.17-4.02(m,1H),3.91(t,J=13.0Hz ,2H),3.72(d,J=8.6Hz,1H),3.53(d,J=8.6Hz,2H),3.01(d,J=5.1Hz,1H),2.33(s,2H),1.85-1.40(m,4H),1.11(d,J=6.4Hz,3H).
[0538]
[0539] Figure 7 The obtained XRPD is shown.
[0540] Example 13
[0541] (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2- Oxa-8-azaspiro[4.5]decan-4-amine free base variant A.
[0542] 12 g of (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine was added to 150 mL of IPA. The mixture was stirred at 70 °C for 30 minutes to dissolve all solids. The mixture was cooled to 25 °C over 2 hours and stirred for another hour. The solids were collected by vacuum filtration and dried under vacuum to give Modification A in free form (10.4 g, 86.7%).
[0543] The free form showed strong degradation when using excipient mixtures containing HPMC.
[0544] The following XRPD data (2-θ value table) were obtained:
[0545]
[0546] 1H NMR (400MHz, DMSO-d6) δ7.72–7.54(m,2H),6.25(s,2H),6.12(s,2H),5.74(d,J=5.3Hz,1H), 4.06(qd,J=6.4,5.1Hz,1H),3.83(tt,J=13.2,5.5Hz,2H),3.66(d,J=8.4Hz,1H),3.48(d,J= 8.5Hz,1H),3.44–3.22(m,3H),2.90(d,J=5.1Hz,1H),1.72(ddd,J=13.2,9.3,3.8Hz,1H),1. 62(ddd,J=13.1,9.0,4.0Hz,1H), 1.48(ddt,J=20.1,13.2,3.5Hz,2H), 1.08(d,J=6.4Hz,3H).
[0547]
[0548] Fig. 9 The obtained XRPD is shown.
[0549] Example 14
[0550] (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2- Oxa-8-azaspiro[4.5]decane-4-amine succinate (2:1) anhydrate variant A
[0551] 1.0 g of (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decane-4-amine monosuccinate hydrate modification HA was added to a 20 mL glass vial and 5 mL of methanol was added. The resulting mixture was stirred at 50° C. for one week. The mixture was filtered and dried to a solid phase at ambient temperature. This gave the hemisuccinate anhydrate modification A.
[0552] The following XRPD data (2-θ value table) were obtained:
[0553]
[0554] 1H NMR (400MHz, DMSO-d6) δ7.77-7.51(m,2H),6.26(s,2H),6.14(s,2H),5.74(d,J=5.4Hz,1H),4.22-3.99(m,1H),3.91(t,J=13.7Hz ,2H),3.72(d,J=8.6Hz,1H),3.54(d,J=8.6Hz,2H),3.02(d,J=5.1Hz,1H),2.34(s,3H),1.86-1.39(m,4H),1.11(d,J=6.4Hz,3H).
[0555]
[0556]
[0557] Figure 8 The obtained XRPD is shown.
[0558] Example 15
[0559] (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2- Oxa-8-azaspiro[4.5]decane-4-amine succinate (2:1) hydrate variant H B :
[0560] During DVS, H A The title compound was obtained.
[0561]
[0562] Example 16
[0563] Comparison of different forms of Examples 6 to 14:
[0564] Select succinate hemihydrate (variant H A ) (Example 6) rather than its anhydrous form (variant A), because the anhydrous form can be rapidly converted to variant H in an aqueous organic solvent mixture containing very small amounts of water (1-2%). A , which prevents the risk of shape changes during stability storage or tableting. In addition, variant H is selected A rather than the hemisuccinate forms, as they are highly hygroscopic and show promise as variant H A A higher degree of polymorphism.
[0565] Succinate variant H of Example 6 A The succinate variant HA of Example 6 showed high solubility in aqueous media, indicating potential good bioavailability, while maintaining a constant water content at 10% RH to 50% RH at room temperature:
[0566]
[0567] FaSSIF=fasting state simulated intestinal fluid (V2: sodium taurocholate 3 mM, lecithin 0.2 mM, sodium chloride 68.6 mM, maleic acid 19.1 mM, sodium hydroxide 101 mM, pancreatin 10.0 mg / l).
[0568] FeSSIF V2 = fed simulated intestinal fluid (V2: 10 mM sodium taurocholate, 2.0 mM lecithin, 0.8 mM sodium oleate, 5.0 mM glycerol monooleate, 125.5 mM sodium chloride, 81.7 mM sodium hydroxide, 55.0 mM maleic acid, pancreatin 40.0 mg / l).
[0569] SGF = simulated gastric fluid (sodium chloride 2 g / l, triton X-100 1 g / l, HCl 0.1 M 100 ml / l.
[0570] At 50°C / 75%RH, when mixed with the following four excipients, the succinate form H A Acceptable levels of degradation were shown in all four experimental excipient blends (the free form showed strong degradation with blends containing HPMC and the adipate salt showed strong degradation with blends containing mannitol, Ac-di-Sol and microcrystalline cellulose):
[0571] Mixture 1: Gelatin powder
[0572] Mixture 2: HPMC
[0573] Mixture 3: MCC PH101 (45 wt-%); lactose monohydrate (44 wt-%), PVP K30 (4 wt-%), Aerosil (0.5 wt-%), magnesium stearate (1.5 wt-%), and 20 wt-% of water was then added to the mixture.
[0574] Mixture 4: Mannitol DC (68.7 wt-%), MCC PH102 (26 wt-%), Ac-Di-Sol (4 wt-%), Aerosil (0.3 wt-%), magnesium stearate (1 wt-%).
Claims
1. (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decane-4-amine succinate (1:1) hydrated form having XRPD peaks at 8.1°±0.2°, 16.3°±0.2°, 17.5°±0.2°, 22.5±0.2° and 26.8±0.2° 2θ.
2. The compound according to claim 1 , having XRPD peaks at 4.4°±0.2°, 8.1°±0.2°, 16.3°±0.2°, 17.5°±0.2°, 20.9°±0.2°, 22.5°±0.2°, 23.0°±0.2°, 23.7°±0.2°, 24.6°±0.2°, 26.8°±0.2°, 27.9°±0.2° and 36.3°±0.2° 2θ.
3. A pharmaceutical composition comprising a compound according to any one of claims 1 to 2 and at least one pharmaceutically acceptable carrier.
4. Use of a compound according to any one of claims 1 to 2 for the preparation of a medicament for the prophylactic or therapeutic treatment of a disease or disorder mediated by SHP2 activity.
5. The use according to claim 4, in, The disease or disorder mediated by SHP2 activity is selected from Noonan syndrome, Leopard syndrome, juvenile myelomonocytic leukemia, neuroblastoma, melanoma, acute myeloid leukemia, breast cancer, esophageal cancer, lung cancer, colon cancer, head cancer, head and neck squamous cell carcinoma, gastric cancer, anaplastic large cell lymphoma and glioblastoma.
6. A combination comprising a compound as defined in any one of claims 1 to 2, and one or more other pharmacologically active compounds, for simultaneous, sequential or separate administration.
7. A combination according to claim 6, wherein the one or more other pharmacologically active compounds comprise an antiproliferative agent.
Citation Information
Patent Citations
Human antithrombin III, DNA sequences therefor, expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby, a process for expressing human antithrombin III, and pharmaceutical compositions comprising it
EP0090505B1
Mammalian cell surface antigens; related reagents
EP1947183B1
Methods of upmodulating adaptive immune response using Anti-PD1 antibodies
US20100028330A1
Method and apparatus for fault-resilient multicast using multiple sources
US20110051726A1
Human antibodies that bind lymphocyte activation gene-3 (LAG-3) and uses thereof
US20110150892A1
